# Medical Question & Answer

**Sample ID**: 18a74c80-2b29-41f8-96b8-e5ae6e63db63
**Dataset Index**: 2451

---

## Question

A 52-year-old woman presents to the physician for a routine physical examination. She has type 2 diabetes that she treats with metformin. Her pulse is 85/min, respiratory rate is 15/min, blood pressure is 162/96 mm Hg, and temperature is 37.0°C (98.6°F). Treatment with a first-line drug is initiated. Which of the following is the most likely effect of this medication?\\n 24-hour urine sodium Aldosterone Angiotensin II Peripheral vascular resistance Renin\\nA Increased Decreased Decreased Decreased Increased\\nB Increased Decreased Decreased Decreased Decreased\\nC Increased Increased Increased Increased Increased\\nD Decreased Increased Increased Decreased Increased\\nE Increased Decreased Increased Decreased Increased
A. A
B. B
C. C
D. E

---

## Answer

> Let's see… What do we have here? The user is asking which pattern of physiologic effects — on 24-hour urine sodium, aldosterone, angiotensin II, peripheral vascular resistance, and renin — would be expected after initiating a first-line antihypertensive for this patient, and to select the correct option among A through E. Let's break this down step-by-step. First, I need to think about what constitutes first-line therapy in current guidelines and whether the vignette implies treatment-naïve hypertension or add-on therapy. Then, I should verify the pharmacologic mechanisms of the major first-line classes and map them to the requested physiologic changes. Next, I will examine which single class plausibly produces natriuresis with suppression of aldosterone and angiotensin II, a fall in peripheral resistance, and a compensatory rise in renin. Finally, I will cross-check the options and confirm the best match, correcting any missteps along the way.

> Let me first confirm the clinical context and what "first-line" implies here. The patient is a 52-year-old woman with type 2 diabetes and newly diagnosed hypertension at 162/96 mmHg; current guidelines recommend initiating one of the five major classes — ACE inhibitor, ARB, thiazide/thiazide-like diuretic, dihydropyridine CCB, or a beta-blocker when compelling indications exist — and then escalating as needed, with combination therapy favored when BP is ≥ 20/10 mmHg above goal, which fits this case [^113u9ZD3] [^112fR7qf] [^114Vx2JC].

> Now, I need to check which class best matches the requested physiologic profile: increased 24-hour urine sodium (natriuresis), decreased aldosterone, decreased angiotensin II, decreased peripheral vascular resistance, and increased renin. Wait, let me verify the renin piece — natriuresis and volume contraction typically trigger a compensatory rise in renin, so an increase in renin would be expected with a diuretic unless there is autonomous aldosterone excess suppressing renin, which is a different phenotype; the question is asking for a first-line drug that produces natriuresis with downstream RAAS activation, not suppression.

> I will now examine thiazide/thiazide-like diuretics because they directly increase renal sodium excretion and thereby reduce plasma volume, which should increase urine sodium and, via volume-mediated signals, stimulate renin release; initially I thought they might also directly suppress aldosterone, but wait, let me verify — thiazides do not directly inhibit aldosterone synthesis or the mineralocorticoid receptor, so any fall in aldosterone would be secondary to volume contraction rather than a direct hormonal blockade, and the expected pattern still fits the requested changes including increased renin and reduced peripheral resistance from volume unloading [^112DUbAJ] [^112EHGs8].

> Next, I should review ACE inhibitors and ARBs. Both reduce angiotensin II signaling and therefore decrease aldosterone and peripheral resistance, but they also remove the negative feedback on renin and typically increase renin; however, they do not directly increase 24-hour urine sodium — in fact, RAS blockade can be associated with sodium retention if not paired with natriuresis, so the lack of natriuresis makes them a poor fit for the requested increase in urine sodium despite their effects on aldosterone, angiotensin II, and resistance [^112VB3LL].

> Let me consider calcium channel blockers. Dihydropyridine CCBs lower blood pressure primarily by vasodilation with decreased peripheral resistance and have minimal direct effects on aldosterone or angiotensin II; they do not increase 24-hour urine sodium, so they cannot account for the natriuresis component in the requested profile, making them an incomplete match [^112DUbAJ].

> Hold on, I should verify beta-blockers as well. Beta-blockers reduce renin release and thus would be expected to decrease angiotensin II and aldosterone, but they do not increase 24-hour urine sodium and may blunt renin, which conflicts with the requested increase in renin; therefore, they do not fit the natriuretic, renin-raising pattern we are looking for [^111CT4G5].

> But wait, what if the stem is hinting at mineralocorticoid receptor antagonism? Spironolactone blocks the MR, reduces aldosterone's effect, lowers peripheral resistance, and can increase renin via natriuresis; however, it is not a first-line agent for uncomplicated hypertension and is reserved for resistant hypertension or specific endocrine indications, so choosing an MRA would violate the "first-line" constraint in a treatment-naïve patient, even though its physiology otherwise aligns with decreased aldosterone effect and increased renin [^1134CPSd] [^112g3vK4] [^115ijeUW].

> Synthesizing this, the only first-line class that increases 24-hour urine sodium, lowers aldosterone indirectly via volume effects, reduces angiotensin II's physiologic drive by volume-mediated feedback, decreases peripheral resistance through volume unloading, and increases renin as a compensatory response is a thiazide or thiazide-like diuretic; among the provided options, Option B matches this pattern precisely, whereas the other options either fail on natriuresis or on renin directionality or are not appropriate first-line choices in this context [^112DUbAJ] [^112EHGs8] [^113u9ZD3] [^116GyidC].

> Final answer: B. Increased 24-hour urine sodium, decreased aldosterone, decreased angiotensin II, decreased peripheral vascular resistance, increased renin — consistent with initiation of a thiazide or thiazide-like diuretic as first-line therapy in a patient with hypertension and type 2 diabetes [^113u9ZD3] [^116GyidC] [^112DUbAJ] [^112EHGs8].

---

The correct answer is **B**. The most likely first-line medication is a thiazide-type diuretic (e.g. chlorthalidone), which increases natriuresis (↑ 24-hour urine sodium), suppresses aldosterone and angiotensin II, reduces peripheral vascular resistance, and reflexively increases renin. This profile matches **Option B** and is consistent with guideline-preferred initial therapy for hypertension in adults, including those with diabetes [^113u9ZD3] [^116GyidC].

---

## Pharmacological mechanism of thiazide diuretics

Thiazide diuretics act on the distal convoluted tubule, inhibiting the sodium-chloride cotransporter (NCC) and increasing sodium and water excretion. This natriuretic effect reduces plasma volume and cardiac output, thereby lowering blood pressure [^notfound].

---

## Expected physiological effects of thiazide diuretics

The following physiological effects are expected with thiazide diuretics:

| **Parameter** | **Expected effect** | **Mechanism** |
|-|-|-|
| 24-hour urine sodium | Increased (↑) | Inhibition of sodium reabsorption in the distal convoluted tubule |
| Aldosterone | Decreased (↓) | Volume depletion and sodium loss suppress aldosterone secretion |
| Angiotensin II | Decreased (↓) | Reduced aldosterone feedback decreases angiotensin II levels |
| Peripheral vascular resistance | Decreased (↓) | Reduced plasma volume and direct vasodilatory effects |
| Renin | Increased (↑) | Volume depletion stimulates renin secretion via the juxtaglomerular apparatus |

---

These effects align with **Option B**, which shows increased 24-hour urine sodium, decreased aldosterone, decreased angiotensin II, decreased peripheral vascular resistance, and increased renin.

---

## Clinical evidence supporting thiazide diuretics as first-line therapy

Thiazide diuretics are recommended as **first-line therapy** for hypertension, including in patients with diabetes, because they effectively lower blood pressure and reduce cardiovascular events [^113u9ZD3] [^116GyidC]. The 2024 ESC guidelines endorse **thiazide-type diuretics** as initial therapy for hypertension, including in patients with diabetes [^113u9ZD3]. Likewise, the 2025 AHA/ACC/AANP guidelines recommend thiazide-type diuretics, **ACE inhibitors, ARBs, and calcium channel blockers** as first-line options for hypertension management [^116GyidC].

---

## Comparison with other antihypertensive medications

- **ACE inhibitors/ARBs**: These medications reduce angiotensin II and aldosterone, decreasing peripheral vascular resistance. However, they typically increase renin levels due to feedback stimulation and do not significantly increase 24-hour urine sodium excretion [^114rwe8p] [^111wysRf].
- **Calcium channel blockers**: These medications reduce peripheral vascular resistance but do not significantly affect aldosterone, angiotensin II, or 24-hour urine sodium excretion.
- **Beta-blockers**: These medications reduce heart rate and cardiac output but do not significantly affect aldosterone, angiotensin II, or 24-hour urine sodium excretion.

---

## Conclusion

The correct answer is **Option B**. Thiazide diuretics are the most likely first-line medication to produce increased 24-hour urine sodium, decreased aldosterone, decreased angiotensin II, decreased peripheral vascular resistance, and increased renin. This profile is consistent with their mechanism of action and current guideline recommendations for hypertension management in patients with diabetes [^notfound].

---

## References

### Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial [^111CT4G5]. Lancet (2015). Excellent credibility.

One hypothesis is that resistant hypertension is predominantly caused by sodium retention, due in part to the reduced doses of diuretics prescribed in recent years; if so, drugs with a diuretic action would be the most effective additional treatment. An alternative hypothesis is that resistant hypertension is a heterogeneous state, with average responses in study cohorts masking substantial individual patient differences. In the latter case, treatment could be stratified by use of biomarkers of sodium/volume status, particularly plasma renin level, to which sodium status is inversely related.

We selected spironolactone as the drug with diuretic action (through blocking the mineralocorticoid receptor) because of observational and limited randomised controlled trial data suggesting good blood pressure-lowering efficacy in resistant hypertension, recently summarised in a meta-analysis. However, spironolactone has not been compared with alternative drugs recommended for resistant hypertension. It has therefore been unknown whether spironolactone is the most effective treatment, and if so, whether this applies to a subset of patients or the majority. We aimed to compare spironolactone with alternative fourth-line treatments targeting different pathogenetic mechanisms: the α₁-adrenoceptor blocker, doxazosin, acting to reduce peripheral resistance, and the β₁-adrenoceptor blocker, bisoprolol, which inhibits the release of renin, and reduces cardiac output. Our primary aim was to determine, for the first time, whether spironolactone is overall the most effective add-on drug treatment for resistant hypertension. The second aim was to determine whether plasma renin levels predict the most effective treatment for individual patients, and whether spironolactone would be most effective in patients with a low plasma renin as a marker of sodium retention. We therefore designed a randomised crossover trial so that each patient's best drug and its predictors could be discovered.

---

### Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies [^115zV8Er]. The Lancet: Diabetes & Endocrinology (2018). Medium credibility.

Implications of all the available evidence

We propose that spironolactone, or amiloride if spironolactone is not tolerated, should be first-line treatment for resistant hypertension, in addition to background treatment with an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, a calcium channel blocker, and a diuretic, in patients with an eGFR greater than 45 mL/min/1.73m² and serum potassium within the normal range. Among this cohort are likely to be some — perhaps many — patients whose hypertension is caused by primary aldosteronism. We encourage a reconsideration of which diagnostic thresholds for primary aldosteronism are appropriate in patients with resistant hypertension, to facilitate recognition of a potentially curable aldosterone-producing adenomas in patients with resistant hypertension.

Understanding the mechanism of the blood pressure-lowering superiority of spironolactone in resistant hypertension would help to delineate the pathophysiological basis of resistant hypertension and provide a rationale for developing alternative treatment strategies for patients in whom spironolactone is poorly tolerated. The hypothesis underpinning PATHWAY-2 was that resistant hypertension is predominantly a sodium-retaining state (despite background treatment with thiazide-type diuretics) and that further diuretic (more correctly, natriuretic) treatment would be the most effective means of lowering blood pressure.PATHWAY-2 incorporated a series of prespecified hormonal and haemodynamic measurements designed to facilitate investigation of the pathophysiology of resistant hypertension and its drug treatment. We now report the results of these analyses, which address three clinically important questions.

---

### Efficacy and safety of mineralocorticoid receptor antagonists for the treatment of low-renin hypertension: a systematic review and meta-analysis [^1132ujvr]. Journal of Human Hypertension (2024). Medium credibility.

Introduction

Hypertension is defined as systolic blood pressure (SBP) ≥ 130 mmHg or diastolic blood pressure (DBP) ≥ 80 mmHg. It affects an estimated 1.28 billion adults worldwide and is a major cause of premature death. Adequate control of this modifiable risk factor is key to reducing cardiovascular disease; a 5 mmHg reduction in SBP is associated with a 10% reduction in major cardiovascular events. However, four out of five hypertensive people do not meet blood pressure (BP) targets and it is estimated that two-thirds of patients will require more than one drug to achieve BP control.

One possible reason for this is that the current one-size-fits-all sequential approach to pharmacotherapy fails to address the underlying pathophysiology of hypertension for the individual. The renin-angiotensin-aldosterone system is a key regulator of BP. Low dietary salt and blood volume stimulate the release of renin, which leads to a cascade of downstream effects including water and salt reabsorption and increased vascular tone mediated by angiotensin II, aldosterone and mineralocorticoid receptor (MR) activation. However, when the renin-angiotensin-aldosterone system is dysregulated, such as in the case of primary aldosteronism (PA), there is a loss of the negative feedback mechanism, leading to inappropriate MR activation promoting excess sodium and water reabsorption, hypertension and end-organ damage. PA is diagnosed by the presence of low renin and an inappropriately normal or elevated plasma aldosterone concentration, resulting in an elevated aldosterone-to-renin ratio (ARR). PA has clear targeted treatment options including medical therapy with MR antagonist (MRA) or adrenalectomy in the case of an aldosterone-producing adenoma. Importantly, adrenalectomy to remove the source of excess aldosterone, and MR blockade are effective in reducing BP and the elevated cardiovascular risk associated with PA. With easier access to renin and aldosterone measurement and advocacy for expanded screening for PA, clinicians are faced with the dilemma of how to manage patients who have low renin but do not meet the diagnostic criteria for PA. This condition, known as low-renin hypertension (LRH), is present in as many as 30% of hypertensive individuals. It is hypothesised that the low renin in the context of hypertension reflects excess MR activation and/or salt reabsorption due to abnormalities in renal sodium handling in the distal nephrons of the kidneys. Current clinical practice guidelines do not provide clear recommendations for the initial choice of monotherapy for people with LRH. In a randomised controlled trial (RCT) of participants with resistant hypertension on three antihypertensives, a lower baseline renin was associated with a greater BP-lowering response with MRA add-on therapy compared to a beta-blocker and an alpha-blocker. This raises the question of whether early targeted MRA treatment in patients with LRH would be beneficial and possibly avoid the need for multiple anti-hypertensives. The findings of individual studies have been conflicting and hence we conducted a systematic review and meta-analysis to combine existing data on the efficacy and tolerability of MRA in LRH.

---

### Primary aldosteronism: an endocrine society clinical practice guideline [^113Yahfk]. The Journal of Clinical Endocrinology and Metabolism (2025). High credibility.

Renin as a biomarker during primary aldosteronism–specific medical therapy: Although aldosterone-directed medical therapy has been beneficial in PA, the optimal dosing and surveillance remain uncertain, and whether renin should guide treatment has been considered by prior studies and consensus groups. Because PA is characterized and diagnosed by aldosterone overproduction despite suppression of renin and angiotensin II, a rise in renin induced by aldosterone-directed medical therapy should reflect reversal of PA pathophysiology that may portend improved clinical outcomes.

---

### Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial [^1134CPSd]. Lancet (2015). Excellent credibility.

Added value of this study

PATHWAY-2 is, to our knowledge, the first randomised controlled trial to compare different blood pressure-lowering treatments in rigorously assessed patients with resistant hypertension, and the first comparison of mineralocorticoid receptor blockade with alternative recommended classes that block the sympathetic nervous system (α blockers and β blockers). The size, crossover design, and hierarchical primary endpoints of PATHWAY-2 enabled demonstration at high significance (p < 0.0001) that spironolactone 25–50 mg/day is by far the most effective drug added to A + C + D, for the treatment of resistant hypertension; blood pressure was controlled (home systolic blood pressure < 135 mm Hg) in 60% of patients. The role of sodium retention in causing resistant hypertension was strongly suggested by a low baseline plasma renin, despite treatment with three drugs which usually elevate renin, and by a significant inverse correlation between renin and blood pressure reduction by spironolactone. The individual crossover data show that spironolactone is the most effective add-on drug, by a large margin, in the overwhelming majority of patients confirmed as adherent, but resistant, to treatment with A + C + D.

Implications of all the available evidence

The unequivocal superiority of spironolactone, together with supportive efficacy and safety data from longer term observational studies, should influence treatment guidelines globally. Whether the superiority is specific for mineralocorticoid receptor blockade, reflecting overlap between primary aldosteronism and resistant hypertension, will require comparison of spironolactone with other types of diuretic. Meanwhile, truly resistant hypertension can now be considered rare and redefined as blood pressure not controlled by A + C + D + spironolactone.

For drug treatment of resistant hypertension, international guidelines specifically refer to fourth-line therapy for patients, whose blood pressure is not controlled by treatment with three drugs, typically A + C + D, where "A" is an angiotensin-converting-enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB), "C" is a calcium channel blocker (CCB), and "D" is a thiazide or thiazide-like diuretic. The choice of fourth-line drug treatment for resistant hypertension has been entirely empirical, reflecting an absence of data from prospective randomised controlled trials comparing different drug treatment options. The underlying pathophysiological basis for resistant hypertension is also poorly understood.

---

### Primary aldosteronism: an endocrine society clinical practice guideline [^112g3vK4]. The Journal of Clinical Endocrinology and Metabolism (2025). High credibility.

Primary aldosteronism-specific therapy — panel recommendation and MRA dosing: The panel issued a conditional recommendation for the use of PA-specific therapies over nonspecific antihypertensive treatments, and the risk of mineralocorticoid receptor antagonist (MRA) side effects can be minimized by commencing at low doses (eg, 12.5–25 mg of spironolactone daily) and increasing the dose gradually (eg, every 2–3 months or sooner if clinically indicated) as required to control BP; measurement of renin during MRA titration can assist treatment decision making, but this is less straightforward if the individual is on other medications that affect renin levels.

---

### Guidance for incorporating FDA processes into the ACC / AHA clinical practice guideline methodology: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^115jPqs2]. Journal of the American College of Cardiology (2025). High credibility.

Resistant hypertension — alternatives to spironolactone and use of adjunct agents — Eplerenone, a more selective steroidal mineralocorticoid receptor antagonist (MRA), is a potential alternative to spironolactone, but randomized controlled trials have not demonstrated reduction of home BP or 24-hour BP at doses between 25 and 100 mg daily when compared with placebo, and effective treatment may require higher dosages; use of nonsteroidal MRA for treating resistant hypertension in patients with moderate to advanced chronic kidney disease (CKD) has not been tested in a clinical trial but may be considered in selected patients with close monitoring of serum potassium. When spironolactone or eplerenone are not tolerated due to side effects or cost, amiloride (10–20 mg) has been shown to be as effective as spironolactone in adults with resistant hypertension. Other alternative fourth- and fifth-line drug therapies include beta-blockers (BBs), alpha blockers, central sympatholytic drugs, and direct vasodilators; however, direct vasodilators such as hydralazine and minoxidil should be used in combination with a BB and a loop diuretic. Aprocitentan, a dual endothelin A and B receptor antagonist, was shown to reduce 24-hour ambulatory SBP by 4 to 6 mm Hg compared with placebo in adults with resistant hypertension when added to a CCB, renin–angiotensin system (RAS) inhibitor, and hydrochlorothiazide (HCTZ), but it has not been directly compared with spironolactone and its side effects of leg edema and fluid retention (9%-18%) may be prohibitive in some patients.

---

### Efficacy and safety of mineralocorticoid receptor antagonists for the treatment of low-renin hypertension: a systematic review and meta-analysis [^116Kp6FY]. Journal of Human Hypertension (2024). Medium credibility.

There are three main limitations of this systematic review and meta-analysis. The population was heterogeneous due to different definitions of LRH. Some authors defined low renin as a value below a prespecified level after stimulation with low salt intake, erect posture and/or diuretics. In contrast, others defined low renin as the lowest tertile of measured renin in a trial population with essential hypertension. In one study done in a Japanese population with hypertension, although low renin was not a study inclusion criterion, authors report that the majority of participants had low renin (mean active plasma renin ranged from 5.7 mU/L to 10.1 mU/L in the different treatment groups). The method of measuring renin varied as well; some studies used PRA whereas other studies used direct renin concentration (DRC). Conversion factors of PRA (ng/mL/h) to DRC (mU/L) of 8.2–12 have been suggested but do not correlate well in the range of interest (PRA < 1 ng/ml/h) or under conditions such as in the presence of high estrogen (lower DRC), congestive heart failure (lower PRA) and concomitant direct renin inhibitor treatment (lower PRA and higher DRC). One study reported measuring renin whilst some participants were on beta-blockers, which can falsely lower renin levels. As such, some participants may have been incorrectly classified as having LRH and therefore confounded any potential differences in the response to treatment. Sensitivity analysis by removing this study increased the mean aggregated difference in SBP in the MRA versus ENaCi meta-analysis but did not reach statistical significance (−6.4 mmHg, 95% CI −21.3, 8.4). Furthermore, PA was not rigorously excluded. Some participants may have undiagnosed PA, which would respond favourably to MRA therapy. PA was excluded using tests with low sensitivity; the presence of hypokalaemia (up to 95% are normokalaemia) and elevated 24-hour urinary aldosterone excretion (accuracy of results depends on whether the sample is collected correctly). One study included participants who had a previous BP-lowering response to spironolactone (> 20 mmHg SBP reduction).

---

### Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies [^111Pydgx]. The Lancet: Diabetes & Endocrinology (2018). Medium credibility.

First, what is the relation between baseline plasma renin, aldosterone, and the aldosterone-to-renin ratio (ARR) and the blood pressure-lowering response to spironolactone, bisoprolol, doxazosin, and placebo? Consistent with our hypothesis that resistant hypertension is predominantly a sodium-retaining state, we expected plasma renin to be relatively suppressed despite background treatment with an ACE inhibitor or an ARB, a CCB, and a diuretic — ie, the so-called A+C+D treatment strategy. A finding of a suppressed renin concentration, despite treatments that usually increase plasma renin, would be consistent with resistant hypertension being a sodium-retaining state. We also hypothesised that the blood pressure-lowering response to spironolactone, but not to other drugs, would be greatest in participants with the lowest plasma renin concentrations and highest ARRs, consistent with sodium retention being largely a consequence of autonomous aldosterone production. The proportion of patients exceeding validated thresholds for the diagnosis of primary aldosteronism was also assessed.

Second, we aimed to assess the haemodynamic responses to the various drug treatments and placebo and their effect on cardiac output, systemic vascular resistance, and thoracic fluid content, testing the hypothesis that the superior action of spironolactone in lowering blood pressure in resistant hypertension would be consistent with those of a diuretic.

Third, we hypothesised that if the superiority of spironolactone in resistant hypertension was due to its natriuretic actions, then amiloride would similarly decrease blood pressure. Like spironolactone, amiloride is a distal tubular diuretic that inhibits the aldosterone-sensitive epithelial sodium channel. Notably, a low-dose thiazide and amiloride combination achieved a greater reduction in blood pressure from baseline than high-dose thiazide alone in patients with hypertension in the PATHWAY-3 trial.

---

### Blood pressure response to mineralocorticoid receptor antagonists or aldosterone synthase inhibitors according to baseline renin levels [^1164wnSZ]. Journal of Human Hypertension (2025). Medium credibility.

Plasma renin is a surrogate marker of sodium retention in hypertension, and its levels are suppressed in conditions of heightened aldosterone production. We performed a random-effects meta-analysis of randomized clinical trials focusing on the impact of mineralocorticoid receptor antagonists (MRA) and aldosterone synthase inhibitors (ASi) on blood pressure according to baseline renin levels. We included four randomized clinical trials, and we found that the response to MRA or ASi was independent of baseline plasma renin levels.

---

### Resistant hypertension: a clinical perspective [^113hqD7A]. Endocrinology and Metabolism Clinics of North America (2019). Medium credibility.

Resistant hypertension is a common clinical entity, defined as suboptimal blood pressure response to multiple therapies after excluding medication nonadherence and secondary forms of hypertension. Patients with resistant hypertension generally share several comorbidities. Resistant hypertension is more common in individuals of African descent. Blood pressure should be optimized using multiple strategies, including lifestyle changes and single-pill combination therapies, with the aim of reducing cardiovascular events while reducing side effects from using antihypertensive therapy. A renin/aldosterone-based diagnostic and treatment approach will help tailor therapy. The use of mineralocorticoid receptor antagonists or amiloride as appropriate is favored.

---

### Hypothesis: reactive increases in plasma renin activity attenuate the fall in blood pressure caused by salt depletion and renin-angiotensin system inhibition [^111rQqqh]. Journal of Hypertension (2025). Medium credibility.

IMPLICATIONS

Resistant hypertension

This hypothesis points to two possible types of resistant hypertension. In one type, PRA remains low during treatment with a natriuretic drug, because there remains an excess of body salt. In the second type, the PRA level is above 4.5 ng/ml/h. BP can be lowered in the first type by increasing the number or dose(s) of natriuretic drugs until PRA rises to 4.5 ng/ml/h, where the increased Ang II-mediated vasoconstriction limits the antihypertensive efficacy of additional natriuresis. In the second type, BP may be lowered by reducing the number or dose of natriuretic drug(s) to reduce the high PRA levels to below 4.5 ng/ml/h, where its effect can be blocked sufficiently by a RAS inhibitor.

Cardiovascular disease

Hypertension is a leading risk factor for cardiovascular disease, and patients with cardiovascular disease have a wide range of on-treatment PRA levels. Thus, in the HOPE trial of patients with cardiovascular disease (CVD), PRA quintiles were 0.29, 0.83, 1.4, 2.3 and 5.9 ng/ml/h when the RAS inhibitor was added. In four reports of patients with CVD, cardiovascular mortality was found to be higher in patients with the highest on-treatment PRA levels despite treatment with a RAS inhibitor. We found evidence that these high PRA levels were likely caused by excessive salt depletion. Mineralocorticoid receptor antagonists (MRAs) and inhibitors of SGLT2 are being increasingly used in the treatment of cardiovascular disease. As blocking the effect of aldosterone with MRAs reduces distal sodium reabsorption, and SGLT2 inhibitors reduce proximal sodium reabsorption, the drugs, particularly when used in combination therapy, have the potential to cause sodium depletion and raise PRA to the point where the renin system is incompletely blocked by ACEIs, ARBs and direct renin inhibitors, thereby attenuating or negating the beneficial effects of RAS inhibition.

---

### First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension [^115x2qQ6]. The Cochrane Database of Systematic Reviews (2018). Low credibility.

Background

This is the first update of a Cochrane Review first published in 2015. Renin angiotensin system (RAS) inhibitors include angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs) and renin inhibitors. They are widely prescribed for treatment of hypertension, especially for people with diabetes because of postulated advantages for reducing diabetic nephropathy and cardiovascular morbidity and mortality. Despite widespread use for hypertension, the efficacy and safety of RAS inhibitors compared to other antihypertensive drug classes remains unclear.

Objectives

To evaluate the benefits and harms of first-line RAS inhibitors compared to other first-line antihypertensive drugs in people with hypertension.

Search Methods

The Cochrane Hypertension Group Information Specialist searched the following databases for randomized controlled trials up to November 2017: the Cochrane Hypertension Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (from 1946), Embase (from 1974), the World Health Organization International Clinical Trials Registry Platform, and ClinicalTrials.gov. We also contacted authors of relevant papers regarding further published and unpublished work. The searches had no language restrictions.

Selection Criteria

We included randomized, active-controlled, double-blinded studies (RCTs) with at least six months follow-up in people with elevated blood pressure (≥ 130/85 mmHg), which compared first-line RAS inhibitors with other first-line antihypertensive drug classes and reported morbidity and mortality or blood pressure outcomes. We excluded people with proven secondary hypertension.

Data Collection and Analysis

Two authors independently selected the included trials, evaluated the risks of bias and entered the data for analysis.

Main Results

This update includes three new RCTs, totaling 45 in all, involving 66,625 participants, with a mean age of 66 years. Much of the evidence for our key outcomes is dominated by a small number of large RCTs at low risk for most sources of bias. Imbalances in the added second-line antihypertensive drugs in some of the studies were important enough for us to downgrade the quality of the evidence. Primary outcomes were all-cause death, fatal and non-fatal stroke, fatal and non-fatal myocardial infarction (MI), fatal and non-fatal congestive heart failure (CHF) requiring hospitalizations, total cardiovascular (CV) events (fatal and non-fatal stroke, fatal and non-fatal MI and fatal and non-fatal CHF requiring hospitalization), and end-stage renal failure (ESRF). Secondary outcomes were systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR). Compared with first-line calcium channel blockers (CCBs), we found moderate-certainty evidence that first-line RAS inhibitors decreased heart failure (HF) (35,143 participants in 5 RCTs, risk ratio (RR) 0.83, 95% confidence interval (CI) 0.77 to 0.90, absolute risk reduction (ARR) 1.2%), and that they increased stroke (34,673 participants in 4 RCTs, RR 1.19, 95% CI 1.08 to 1.32, absolute risk increase (ARI) 0.7%). Moderate-certainty evidence showed that first-line RAS inhibitors and first-line CCBs did not differ for all-cause death (35,226 participants in 5 RCTs, RR 1.03, 95% CI 0.98 to 1.09); total CV events (35,223 participants in 6 RCTs, RR 0.98, 95% CI 0.93 to 1.02); and total MI (35,043 participants in 5 RCTs, RR 1.01, 95% CI 0.93 to 1.09). Low-certainty evidence suggests they did not differ for ESRF (19,551 participants in 4 RCTs, RR 0.88, 95% CI 0.74 to 1.05). Compared with first-line thiazides, we found moderate-certainty evidence that first-line RAS inhibitors increased HF (24,309 participants in 1 RCT, RR 1.19, 95% CI 1.07 to 1.31, ARI 1.0%), and increased stroke (24,309 participants in 1 RCT, RR 1.14, 95% CI 1.02 to 1.28, ARI 0.6%). Moderate-certainty evidence showed that first-line RAS inhibitors and first-line thiazides did not differ for all-cause death (24,309 participants in 1 RCT, RR 1.00, 95% CI 0.94 to 1.07); total CV events (24,379 participants in 2 RCTs, RR 1.05, 95% CI 1.00 to 1.11); and total MI (24,379 participants in 2 RCTs, RR 0.93, 95% CI 0.86 to 1.01). Low-certainty evidence suggests they did not differ for ESRF (24,309 participants in 1 RCT, RR 1.10, 95% CI 0.88 to 1.37). Compared with first-line beta-blockers, low-certainty evidence suggests that first-line RAS inhibitors decreased total CV events (9239 participants in 2 RCTs, RR 0.88, 95% CI 0.80 to 0.98, ARR 1.7%), and decreased stroke (9193 participants in 1 RCT, RR 0.75, 95% CI 0.63 to 0.88, ARR 1.7%). Low-certainty evidence suggests that first-line RAS inhibitors and first-line beta-blockers did not differ for all-cause death (9193 participants in 1 RCT, RR 0.89, 95% CI 0.78 to 1.01); HF (9193 participants in 1 RCT, RR 0.95, 95% CI 0.76 to 1.18); and total MI (9239 participants in 2 RCTs, RR 1.05, 95% CI 0.86 to 1.27). Blood pressure comparisons between first-line RAS inhibitors and other first-line classes showed either no differences or small differences that did not necessarily correlate with the differences in the morbidity outcomes. There is no information about non-fatal serious adverse events, as none of the trials reported this outcome.

Authors' Conclusions

All-cause death is similar for first-line RAS inhibitors and first-line CCBs, thiazides and beta-blockers. There are, however, differences for some morbidity outcomes. First-line thiazides caused less HF and stroke than first-line RAS inhibitors. First-line CCBs increased HF but decreased stroke compared to first-line RAS inhibitors. The magnitude of the increase in HF exceeded the decrease in stroke. Low-quality evidence suggests that first-line RAS inhibitors reduced stroke and total CV events compared to first-line beta-blockers. The small differences in effect on blood pressure between the different classes of drugs did not correlate with the differences in the morbidity outcomes.

---

### 2025 AHA / ACC / AANP / AAPA / ABC / ACCP / ACPM / AGS / AMA / ASPC / NMA / PCNA / SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^115ijeUW]. Hypertension (2025). High credibility.

Resistant hypertension — alternatives when MRA not tolerated — When spironolactone or eplerenone are not tolerated due to side effects or cost, amiloride (10–20 mg) has been shown to be as effective as spironolactone in adults with resistant hypertension. Other alternative fourth- and fifth-line drug therapies include BBs, alpha blockers, central sympatholytic drugs, and direct vasodilators; however, direct vasodilators such as hydralazine and minoxidil should be used in combination with a BB and a loop diuretic given their effects on sympathetic tone, sodium reabsorption, and fluid retention. Aprocitentan, a dual endothelin A and B receptor antagonist, was shown to reduce 24-hour ambulatory SBP by 4 to 6 mm Hg compared with placebo in adults with resistant hypertension when added to a CCB, RAS inhibitor, and HCTZ, but it has not been directly compared with spironolactone and the side effects of leg edema and fluid retention (9%-18%) may be prohibitive in some patients.

---

### 2025 AHA / ACC / AANP / AAPA / ABC / ACCP / ACPM / AGS / AMA / ASPC / NMA / PCNA / SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^115noGF9]. Hypertension (2025). High credibility.

Resistant hypertension — alternatives when spironolactone/eplerenone are not tolerated — When spironolactone or eplerenone are not tolerated due to side effects or cost, amiloride (10–20 mg) has been shown to be as effective as spironolactone in adults with resistant hypertension. Other alternative fourth- and fifth-line drug therapies include beta blockers (BBs), alpha blockers, central sympatholytic drugs, and direct vasodilators; however, direct vasodilators such as hydralazine and minoxidil should be used in combination with a BB and a loop diuretic. Aprocitentan, a dual endothelin A and B receptor antagonist, was shown to reduce 24-hour ambulatory SBP by 4 to 6 mm Hg compared with placebo when added to a CCB, renin-angiotensin system (RAS) inhibitor, and HCTZ, but it has not been directly compared with spironolactone and leg edema and fluid retention (9%-18%) may be prohibitive in some patients.

---

### Guidance for incorporating FDA processes into the ACC / AHA clinical practice guideline methodology: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^116qzgzw]. Journal of the American College of Cardiology (2025). High credibility.

2025 High Blood Pressure Guideline — secondary hypertension: primary aldosteronism should be suspected with features such as "Resistant hypertension; hypertension with hypokalemia (spontaneous or diuretic induced); hypertension and muscle cramps or weakness; hypertension and incidentally discovered adrenal mass; hypertension and obstructive sleep apnea; hypertension and family history of early-onset hypertension or stroke", with screening by "Electrolytes, including sodium and potassium, plasma aldosterone/renin activity ratio (correction of hypokalemia and withdrawal of MRA for 4–6 wks)" and confirmatory options "Oral sodium loading test (with 24-h urine aldosterone) or IV saline infusion test with plasma aldosterone at 4 h of infusion or captopril suppression test (in patients not on ACEI or ARB treatment), adrenal CT scan, adrenal vein sampling".

---

### Primary aldosteronism: an endocrine society clinical practice guideline [^115Rhs2M]. The Journal of Clinical Endocrinology and Metabolism (2025). High credibility.

Primary aldosteronism — choice of mineralocorticoid receptor antagonist: In individuals with primary aldosteronism receiving PA-specific medical therapy, we suggest spironolactone over other mineralocorticoid receptor antagonists (MRAs) due to its low cost and widespread availability. The recommendation is driven by the availability and low cost of spironolactone over other MRAs; however, all MRAs, when titrated to equivalent potencies, are anticipated to have similar efficacy in treating primary aldosteronism, and MRAs with greater mineralocorticoid receptor selectivity and fewer androgen/progesterone receptor-mediated side effects may be preferred; when initiating an MRA, consider hypertension severity for dosing and potential discontinuation of other antihypertensive medications, and monitor potassium, renal function, renin (concentration or activity), and blood pressure response during follow-up to guide MRA dose titration.

---

### What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment? [^112fR7qf]. Cardiovascular Diabetology (2012). Low credibility.

Introduction

Hypertension is a highly prevalent disease with a major associated risk for cardiovascular (CV) morbidity and mortality. The majority of patients with hypertension require more than one antihypertensive agent to achieve and maintain guideline-recommended blood pressure (BP) goals. Identifying the most appropriate combination therapy for each patient based on individual risk factors and comorbidities is important for risk management. Increasingly, single-pill combinations (SPCs) containing two or more antihypertensive agents with complementary mechanisms of action are available. These offer potential advantages, including simplification of treatment regimens, more convenient drug administration and reduced healthcare costs. Evidence from meta-analyses has shown that the use of antihypertensive SPCs compared with corresponding free-drug combinations is associated with significantly greater rates of treatment adherence to medication and potential advantages in terms of BP improvements and adverse effects. A large retrospective database study of an angiotensin II receptor blocker (ARB) plus a calcium channel blocker (CCB) in two-drug SPCs has also shown greater levels of adherence compared with the corresponding free-pill ARB/CCB regimens. Treatment adherence is an important issue for a chronic disease such as hypertension, with improvements in adherence expected to result in better long-term clinical outcomes, including reduced CV and renal morbidity/mortality. This review will consider the choice of agents for combination therapy using two-drug SPCs and the rationale for using particular combinations in patients with hypertension and renal impairment.

Why should early combination therapy be considered?

Worldwide guidelines recommend combination therapy as a first-line treatment option for hypertension likely not to be controlled on monotherapy (e.g. 20/10 mmHg above target BP) because of evidence showing that only a minority of patients will achieve and maintain BP goals on monotherapy. The recent re-appraisal of the European guidelines also recommended the preferential use of SPCs to improve adherence.

There are a number of compelling reasons why early combination therapy should be used in patients with hypertension (Table 1), including lack of efficacy with monotherapy, greater BP control and attenuation of side effects associated with monotherapeutic treatment. In addition, hypertensive patients with comorbidities, such as renal disease, might benefit from additional effects of multiple antihypertensive agents, beyond those related to BP lowering.

Table 1
Rationale for and potential advantages of early SPC antihypertensive therapy

Abbreviations: BP = blood pressure; CCB = calcium channel blocker; DBP = diastolic blood pressure; RAS = renin-angiotensin system; SBP = systolic blood pressure; SPC = single-pill combination

---

### Primary aldosteronism: an endocrine society clinical practice guideline [^116zSMdP]. The Journal of Clinical Endocrinology and Metabolism (2025). High credibility.

Regarding medical management for primary aldosteronism, more specifically with respect to general principles, ES 2025 guidelines recommend to consider increasing PA-specific medical therapy in patients with PA receiving such therapy whose hypertension is not controlled and renin is suppressed, to raise renin levels.

---

### 2025 AHA / ACC / AANP / AAPA / ABC / ACCP / ACPM / AGS / AMA / ASPC / NMA / PCNA / SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^1175cRQ2]. Hypertension (2025). High credibility.

Resistant hypertension — initial combination therapy and mineralocorticoid receptor antagonists (MRA) — Antihypertensive drug therapy should start with a combination of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB), a calcium channel blocker (CCB), and a diuretic, and replacing thiazide-type diuretics with thiazide-like diuretics may offer additional BP reduction and cardiovascular protection. Randomized controlled trials (RCTs) have shown that the addition of spironolactone (25–50 mg/day) as the fourth drug reduced home and 24-hour systolic BP (SBP) by 6.6 to 8.7 mm Hg compared with placebo in patients with resistant hypertension and eGFR ≥ 45 mL/ min/1.73 m², with reductions greater than with doxazosin, bisoprolol, or clonidine. Nevertheless, 4% to 40% of adults with resistant hypertension cannot tolerate spironolactone due to hyperkalemia or antiandrogenic side effects; eplerenone is a potential alternative, but RCTs have not demonstrated reduction of home BP or 24-hour BP at doses between 25 and 100 mg daily and effective treatment may require higher dosages, and nonsteroidal MRA for moderate to advanced chronic kidney disease (CKD) has not been tested in a clinical trial but may be considered in selected patients with close monitoring of serum potassium.

---

### Primary aldosteronism: an endocrine society clinical practice guideline [^112DZqc9]. The Journal of Clinical Endocrinology and Metabolism (2025). High credibility.

Primary aldosteronism — Justification for Recommendation 10 states that although the evidence is limited and indirect, amiloride seems to be as effective as spironolactone in reducing BP in individuals with resistant hypertension and both drugs are low cost and both improve QOL; nevertheless, there is a lack of direct clinical evidence to recommend ENaC amiloride over MRA spironolactone as first-line therapy, and an MRA should be the preferred treatment in PA based on a small study of 10 individuals in which spironolactone (400 mg/day) had greater BP-lowering effects than amiloride (40 mg/day); when spironolactone is not tolerated and other MRAs are not available, amiloride may be an alternative therapy in the management of PA.

---

### 2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the international society of hypertension (ISH) and the European renal association (ERA) [^113W3b3c]. Journal of Hypertension (2023). High credibility.

Regarding medical management for hypertension, more specifically with respect to choice of antihypertensives, initial therapy, ESH 2023 guidelines recommend to do not combine two renin-angiotensin system blockers due to the increased risk of adverse events, particularly AKI.

---

### Telmisartan [^114rwe8p]. FDA (2025). Medium credibility.

12.2 Pharmacodynamics

In normal volunteers, a dose of telmisartan 80 mg inhibited the pressor response to an intravenous infusion of angiotensin II by about 90% at peak plasma concentrations with approximately 40% inhibition persisting for 24 hours.

Plasma concentration of angiotensin II and plasma renin activity (PRA) increased in a dose-dependent manner after single administration of telmisartan to healthy subjects and repeated administration to hypertensive patients. The once-daily administration of up to 80 mg telmisartan to healthy subjects did not influence plasma aldosterone concentrations. In multiple dose studies with hypertensive patients, there were no clinically significant changes in electrolytes (serum potassium or sodium), or in metabolic function (including serum levels of cholesterol, triglycerides, HDL, LDL, glucose, or uric acid).

In 30 hypertensive patients with normal renal function treated for 8 weeks with telmisartan 80 mg or telmisartan 80 mg in combination with hydrochlorothiazide 12.5 mg, there were no clinically significant changes from baseline in renal blood flow, glomerular filtration rate, filtration fraction, renovascular resistance, or creatinine clearance.

---

### 2024 ESC guidelines for the management of elevated blood pressure and hypertension [^116tMtLT]. European Heart Journal (2024). High credibility.

Regarding diagnostic investigations for hypertension, more specifically with respect to evaluation for primary hyperaldosteronism, ESC 2024 guidelines recommend to consider obtaining renin and aldosterone measurements to screen for primary aldosteronism in all adult patients with confirmed HTN (BP ≥ 140/90 mmHg).

---

### Efficacy of low-dose spironolactone in subjects with resistant hypertension [^111xmw5e]. American Journal of Hypertension (2003). Low credibility.

Background

Previous reports have demonstrated the antihypertensive efficacy of high doses of spironolactone in subjects with primary aldosteronism and, to a lesser degree, subjects with resistant hypertension.

Methods

In current analysis, we examined the antihypertensive benefit of adding low-dose spironolactone to multidrug regimens that included a diuretic and an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) in subjects with resistant hypertension with and without primary aldosteronism. Subjects referred for resistant hypertension were evaluated with an early morning plasma renin activity, 24-h urinary aldosterone and sodium during a high dietary salt ingestion. The diagnosis of primary aldosteronism was confirmed with a renin activity < 1.0 ng/mL/h, urinary aldosterone > 12 mug/24 h and urinary sodium > 200 mEq/24 h. After biochemical evaluation, spironolactone (12.5 to 25 mg/d) was added to each subject's antihypertensive regimen. If blood pressure (BP) remained uncontrolled, the dose of spironolactone was titrated up to 50 mg/d. Follow-up BP was determined at 6 weeks, 3 months, and 6 months.

Results

A total number of 76 subjects were included in the analysis, 34 of whom had biochemical primary aldosteronism. Low-dose spironolactone was associated with an additional mean decrease in BP of 21 ± 21/10 ± 14 mm Hg at 6 weeks and 25 ± 20/12 ± 12 mm Hg at 6-month follow-up. The BP reduction was similar in subjects with and without primary aldosteronism and was additive to the use of ACE inhibitors, ARBs, and diuretics.

Conclusions

We conclude that low-dose spironolactone provides significant additive BP reduction in African American and white subjects with resistant hypertension with and without primary aldosteronism.

---

### Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies [^112EHGs8]. The Lancet: Diabetes & Endocrinology (2018). Medium credibility.

The rationale for the extra measurements or intervention that we report here was to link the pathophysiology of resistant hypertension with response to treatment. This link became of particular interest when the primary outcome showed spironolactone to be substantially superior to the alternatives. Although this outcome was scarcely a complete surprise, we had not expected superiority to be exhibited across almost the entire distribution of plasma renin, with the crossover design permitting demonstration that only ten (3%) of 326 patients in PATHWAY-2 had a plasma renin concentration that predicted better blood pressure response to α blockade or β blockade than to spironolactone. It seems reasonable now to conclude that resistant hypertension, as previously suspected, is predominantly a salt-retaining state, often caused by primary or secondary aldosteronism.

One of the best measures of sodium balance is plasma renin, as shown by the dose-related, several-times increases in plasma renin caused by each of the diuretic treatments in PATHWAY-3. Definition of normal ranges for plasma renin is difficult in patients receiving multiple antihypertensive drugs — in particular the A+C+D classes required for a diagnosis of resistant hypertension, all of which increase concentrations of plasma renin. However, the median plasma renin value of 34 mU/L in PATHWAY-2 was only three times greater than the median value (11 mU/L) in the 605 patients with untreated hypertension in PATHWAY-1, who had similar blood pressure values on no treatment. Because we can compare the same patient's response to each of a diuretic drug (spironolactone; efficacy inversely correlated to renin) and RAS-blocking drug (bisoprolol; positively correlated), we can establish the point between the bottom and top of the renin distribution at which the diuretic is predicted by the plasma renin concentration to be less effective than the RAS blocker (appendix). In the patients with resistant hypertension in PATHWAY-2, this point lies at the extreme right of the renin distribution, with all but 3% of patients predicted to respond better to diuretic than RAS blocker. This finding is in striking contrast to the effects seen in the previously untreated patients of PATHWAY-1, in whom a crossover comparison of hydrochlorothiazide 25 mg and losartan 100 mg was done, and the diuretic efficacy is predicted by plasma renin concentration to exceed that of the RAS blocker in fewer than half the patients. Notably, the relatively low median plasma renin in PATHWAY-2 is not due to impaired renal clearance because the eGFR was normal. Nor was it due to excessive dietary sodium intake as the 24 h urinary sodium was typical of that seen in western Europe.

---

### First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension [^1143bGFm]. The Cochrane Database of Systematic Reviews (2015). Low credibility.

Background

Renin-angiotensin system (RAS) inhibitors are widely prescribed for treatment of hypertension, especially for diabetic patients on the basis of postulated advantages for the reduction of diabetic nephropathy and cardiovascular morbidity and mortality. Despite widespread use of angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) for hypertension in both diabetic and non-diabetic patients, the efficacy and safety of RAS inhibitors compared to other antihypertensive drug classes remains unclear.

Objectives

To evaluate the benefits and harms of first-line RAS inhibitors compared to other first-line antihypertensive drugs in patients with hypertension.

Search Methods

We searched the Cochrane Hypertension Group's Specialised Register, MEDLINE, MEDLINE In-Process, EMBASE and ClinicalTrials.gov for randomized controlled trials up to November 19, 2014 and the Cochrane Central Register of Controlled Trials (CENTRAL) up to October 19, 2014. The WHO International Clinical Trials Registry Platform (ICTRP) is searched for inclusion in the Cochrane Hypertension Group's Specialised Register.

Selection Criteria

We included randomized, active-controlled, double-blinded studies with at least six months follow-up in people with primary elevated blood pressure (≥ 130/85 mmHg), which compared first-line RAS inhibitors with other first-line antihypertensive drug classes and reported morbidity and mortality or blood pressure outcomes. Patients with proven secondary hypertension were excluded.

Data Collection and Analysis

Two authors independently selected the included trials, evaluated the risk of bias and entered the data for analysis.

Main Results

We included 42 studies, involving 65,733 participants, with a mean age of 66 years. Much of the evidence for our key outcomes is dominated by a small number of large studies at a low risk of bias for most sources of bias. Imbalances in the added second-line antihypertensive drugs in some of the studies were important enough for us to downgrade the quality of the evidence. Primary outcomes were all-cause death, fatal and non-fatal stroke, fatal and non-fatal myocardial infarction (MI), fatal and non-fatal congestive heart failure (CHF) requiring hospitalization, total cardiovascular (CV) events (consisted of fatal and non-fatal stroke, fatal and non-fatal MI and fatal and non-fatal CHF requiring hospitalizations), and ESRF. Secondary outcomes were systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR). Compared with first-line calcium channel blockers (CCBs), we found moderate quality evidence that first-line RAS inhibitors decreased heart failure (HF) (35,143 participants in 5 RCTs, RR 0.83, 95% CI 0.77 to 0.90, ARR 1.2%), and moderate quality evidence that they increased stroke (34,673 participants in 4 RCTs, RR 1.19, 95% CI 1.08 to 1.32, ARI 0.7%). They had similar effects on all-cause death (35,226 participants in 5 RCTs, RR 1.03, 95% CI 0.98 to 1.09; moderate quality evidence), total CV events (35,223 participants in 6 RCTs, RR 0.98, 95% CI 0.93 to 1.02; moderate quality evidence), total MI (35,043 participants in 5 RCTs, RR 1.01, 95% CI 0.93 to 1.09; moderate quality evidence). The results for ESRF do not exclude potentially important differences (19,551 participants in 4 RCTs, RR 0.88, 95% CI 0.74 to 1.05; low quality evidence). Compared with first-line thiazides, we found moderate quality evidence that first-line RAS inhibitors increased HF (24,309 participants in 1 RCT, RR 1.19, 95% CI 1.07 to 1.31, ARI 1.0%), and increased stroke (24,309 participants in 1 RCT, RR 1.14, 95% CI 1.02 to 1.28, ARI 0.6%). They had similar effects on all-cause death (24,309 participants in 1 RCT, RR 1.00, 95% CI 0.94 to 1.07; moderate quality evidence), total CV events (24,379 participants in 2 RCTs, RR 1.05, 95% CI 1.00 to 1.11; moderate quality evidence), and total MI (24,379 participants in 2 RCTs, RR 0.93, 95% CI 0.86 to 1.01; moderate quality evidence). Results for ESRF do not exclude potentially important differences (24,309 participants in 1 RCT, RR 1.10, 95% CI 0.88 to 1.37; low quality evidence). Compared with first-line beta-blockers, we found low quality evidence that first-line RAS inhibitors decreased total CV events (9239 participants in 2 RCTs, RR 0.88, 95% CI 0.80 to 0.98, ARR 1.7%), and low quality evidence that they decreased stroke (9193 participants in 1 RCT, RR 0.75, 95% CI 0.63 to 0.88, ARR 1.7%). Our analyses do not exclude potentially important differences between first-line RAS inhibitors and beta-blockers on all-cause death (9193 participants in 1 RCT, RR 0.89, 95% CI 0.78 to 1.01; low quality evidence), HF (9193 participants in 1 RCT, RR 0.95, 95% CI 0.76 to 1.18; low quality evidence), and total MI (9239 participants in 2 RCTs, RR 1.05, 95% CI 0.86 to 1.27; low quality evidence). Blood pressure comparisons between RAS inhibitors and other classes showed either no differences or small differences that did not necessarily correlate with the differences in the morbidity outcomes. In the protocol, we identified non-fatal serious adverse events (SAE) as a primary outcome. However, when we extracted the data from included studies, none of them reported total SAE in a manner that could be used in the review. Therefore, there is no information about SAE in the review.

Authors' Conclusions

We found predominantly moderate quality evidence that all-cause mortality is similar when first-line RAS inhibitors are compared to other first-line antihypertensive agents. First-line thiazides caused less HF and stroke than first-line RAS inhibitors. The quality of the evidence comparing first-line beta-blockers and first-line RAS inhibitors was low and the lower risk of total CV events and stroke seen with RAS inhibitors may change with the publication of additional trials. Compared with first-line CCBs, first-line RAS inhibitors reduced HF but increased stroke. The magnitude of the reduction in HF exceeded the increase in stroke. The small differences in effect on blood pressure between the different classes of drugs did not correlate with the differences in the primary outcomes.

---

### First-line diuretics versus other classes of antihypertensive drugs for hypertension [^114VRfqY]. The Cochrane Database of Systematic Reviews (2023). Medium credibility.

Background

Different first-line drug classes for patients with hypertension are often assumed to have similar effectiveness with respect to reducing mortality and morbidity outcomes, and lowering blood pressure. First-line low-dose thiazide diuretics have been previously shown to have the best mortality and morbidity evidence when compared with placebo or no treatment. Head-to-head comparisons of thiazides with other blood pressure-lowering drug classes would demonstrate whether there are important differences.

Objectives

To compare the effects of first-line diuretic drugs with other individual first-line classes of antihypertensive drugs on mortality, morbidity, and withdrawals due to adverse effects in patients with hypertension. Secondary objectives included assessments of the need for added drugs, drug switching, and blood pressure-lowering.

Search Methods

Cochrane Hypertension's Information Specialist searched the Cochrane Hypertension Specialized Register, CENTRAL, MEDLINE, Embase, and trials registers to March 2021. We also checked references and contacted study authors to identify additional studies. A top-up search of the Specialized Register was carried out in June 2022.

Selection Criteria

Randomized active comparator trials of at least one year's duration were included. Trials had a clearly defined intervention arm of a first-line diuretic (thiazide, thiazide-like, or loop diuretic) compared to another first-line drug class: beta-blockers, calcium channel blockers, alpha adrenergic blockers, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blockers, direct renin inhibitors, or other antihypertensive drug classes. Studies had to include clearly defined mortality and morbidity outcomes (serious adverse events, total cardiovascular events, stroke, coronary heart disease (CHD), congestive heart failure, and withdrawals due to adverse effects).

Data Collection and Analysis

We used standard Cochrane methodological procedures.

Main Results

We included 20 trials with 26 comparator arms randomizing over 90,000 participants. The findings are relevant to first-line use of drug classes in older male and female hypertensive patients (aged 50 to 75) with multiple co-morbidities, including type 2 diabetes. First-line thiazide and thiazide-like diuretics were compared with beta-blockers (six trials), calcium channel blockers (eight trials), ACE inhibitors (five trials), and alpha-adrenergic blockers (three trials); other comparators included angiotensin II receptor blockers, aliskiren (a direct renin inhibitor), and clonidine (a centrally acting drug). Only three studies reported data for total serious adverse events: two studies compared diuretics with calcium channel blockers and one with a direct renin inhibitor. Compared to first-line beta-blockers, first-line thiazides probably result in little to no difference in total mortality (risk ratio (RR) 0.96, 95% confidence interval (CI) 0.84 to 1.10; 5 trials, 18,241 participants; moderate-certainty), probably reduce total cardiovascular events (5.4% versus 4.8%; RR 0.88, 95% CI 0.78 to 1.00; 4 trials, 18,135 participants; absolute risk reduction (ARR) 0.6%, moderate-certainty), may result in little to no difference in stroke (RR 0.85, 95% CI 0.66 to 1.09; 4 trials, 18,135 participants; low-certainty), CHD (RR 0.91, 95% CI 0.78 to 1.07; 4 trials, 18,135 participants; low-certainty), or heart failure (RR 0.69, 95% CI 0.40 to 1.19; 1 trial, 6569 participants; low-certainty), and probably reduce withdrawals due to adverse effects (10.1% versus 7.9%; RR 0.78, 95% CI 0.71 to 0.85; 5 trials, 18,501 participants; ARR 2.2%; moderate-certainty). Compared to first-line calcium channel blockers, first-line thiazides probably result in little to no difference in total mortality (RR 1.02, 95% CI 0.96 to 1.08; 7 trials, 35,417 participants; moderate-certainty), may result in little to no difference in serious adverse events (RR 1.09, 95% CI 0.97 to 1.24; 2 trials, 7204 participants; low-certainty), probably reduce total cardiovascular events (14.3% versus 13.3%; RR 0.93, 95% CI 0.89 to 0.98; 6 trials, 35,217 participants; ARR 1.0%; moderate-certainty), probably result in little to no difference in stroke (RR 1.06, 95% CI 0.95 to 1.18; 6 trials, 35,217 participants; moderate-certainty) or CHD (RR 1.00, 95% CI 0.93 to 1.08; 6 trials, 35,217 participants; moderate-certainty), probably reduce heart failure (4.4% versus 3.2%; RR 0.74, 95% CI 0.66 to 0.82; 6 trials, 35,217 participants; ARR 1.2%; moderate-certainty), and may reduce withdrawals due to adverse effects (7.6% versus 6.2%; RR 0.81, 95% CI 0.75 to 0.88; 7 trials, 33,908 participants; ARR 1.4%; low-certainty). Compared to first-line ACE inhibitors, first-line thiazides probably result in little to no difference in total mortality (RR 1.00, 95% CI 0.95 to 1.07; 3 trials, 30,961 participants; moderate-certainty), may result in little to no difference in total cardiovascular events (RR 0.97, 95% CI 0.92 to 1.02; 3 trials, 30,900 participants; low-certainty), probably reduce stroke slightly (4.7% versus 4.1%; RR 0.89, 95% CI 0.80 to 0.99; 3 trials, 30,900 participants; ARR 0.6%; moderate-certainty), probably result in little to no difference in CHD (RR 1.03, 95% CI 0.96 to 1.12; 3 trials, 30,900 participants; moderate-certainty) or heart failure (RR 0.94, 95% CI 0.84 to 1.04; 2 trials, 30,392 participants; moderate-certainty), and probably reduce withdrawals due to adverse effects (3.9% versus 2.9%; RR 0.73, 95% CI 0.64 to 0.84; 3 trials, 25,254 participants; ARR 1.0%; moderate-certainty). Compared to first-line alpha-blockers, first-line thiazides probably result in little to no difference in total mortality (RR 0.98, 95% CI 0.88 to 1.09; 1 trial, 24,316 participants; moderate-certainty), probably reduce total cardiovascular events (12.1% versus 9.0%; RR 0.74, 95% CI 0.69 to 0.80; 2 trials, 24,396 participants; ARR 3.1%; moderate-certainty) and stroke (2.7% versus 2.3%; RR 0.86, 95% CI 0.73 to 1.01; 2 trials, 24,396 participants; ARR 0.4%; moderate-certainty), may result in little to no difference in CHD (RR 0.98, 95% CI 0.86 to 1.11; 2 trials, 24,396 participants; low-certainty), probably reduce heart failure (5.4% versus 2.8%; RR 0.51, 95% CI 0.45 to 0.58; 1 trial, 24,316 participants; ARR 2.6%; moderate-certainty), and may reduce withdrawals due to adverse effects (1.3% versus 0.9%; RR 0.70, 95% CI 0.54 to 0.89; 3 trials, 24,772 participants; ARR 0.4%; low-certainty). For the other drug classes, data were insufficient. No antihypertensive drug class demonstrated any clinically important advantages over first-line thiazides.

Authors' Conclusions

When used as first-line agents for the treatment of hypertension, thiazides and thiazide-like drugs likely do not change total mortality and likely decrease some morbidity outcomes such as cardiovascular events and withdrawals due to adverse effects, when compared to beta-blockers, calcium channel blockers, ACE inhibitors, and alpha-blockers.

---

### Efficacy and safety of mineralocorticoid receptor antagonists for the treatment of low-renin hypertension: a systematic review and meta-analysis [^116t3fQ6]. Journal of Human Hypertension (2024). Medium credibility.

Discussion

This systematic review and meta-analysis suggest that MRA are more effective at lowering BP in LRH compared to placebo and ACEi/ARB, particularly for SBP. Two studies with follow-ups of more than three months suggest that this difference in the BP-lowering effect may be maintained. There was a trend towards favouring MRA use over ACEi/ARB for lowering DBP as well. This was significant when studies assessed to be high risk of bias were removed. This supports the notion that further suppression of the renin-angiotensin system is less effective in a low-renin state compared to blocking MR activation. This is an important finding as ACEi/ARB are commonly prescribed first-line anti-hypertensives. It is possible that this differential BP response to MRA would have been strengthened if more studies with longer follow-up were available due to the aldosterone escape phenomenon described with the chronic use of ACEi.

In the MRA versus diuretic meta-analysis, there was a trend towards favouring MRA lowering SBP compared to thiazide and thiazide-like diuretics. This supports the hypothesis that in addition to an excess salt/volume state, there is inappropriate MR activation in many people with LRH. This difference in efficacy was increased when data from the Adlin et al study, which had a more relaxed LRH definition including low-normal renin, was removed. Thiazide and thiazide-like diuretics may be a preferable second or third-line antihypertensive for LRH compared to beta-blockers or ACEi due to their natriuretic effect. Turner et al reported that in 363 participants with essential hypertension, a lower plasma renin activity (PRA) predicted a better blood pressure-lowering response to hydrochlorothiazide (12.5–25 mg/day) compared to atenolol (50–100 mg/day), both as monotherapy and as an add-on. In a retrospective analysis, among 313 participants with PRA in the lowest tertile (< 0.74 ng/ml/h), it was hypothesised excess sodium and expanded volume contributed to hypertension, natriuretic anti-hypertensives, diuretics and calcium channel blockers, were more effective in lowering SBP (−16 versus −6 mmHg, p < 0.001) and DBP (−8 versus −5mmHg, p = 0.008) compared to renin-angiotensin targeting anti-hypertensives, beta-blockers and ACEi.

---

### VA / DoD clinical practice guideline for the diagnosis and management of hypertension in the primary care setting [^111K9iw2]. VA/DoD (2020). High credibility.

Resistant hypertension — spironolactone add-on therapy: For patients with resistant hypertension (defined as those who are not adequately controlled with maximally tolerated dose of triple therapy [i.e., a thiazide-type diuretic, calcium channel blockers, and angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker]), we suggest adding spironolactone in those patients without contraindications (Weak for | Reviewed, New-replaced). The mineralocorticoid receptor antagonist spironolactone more effectively reduced SBP and DBP compared to placebo when added as the fourth agent to the treatment regimen of patients with resistant HTN, and in patients with a history of hyperkalemia and diminished renal function, spironolactone should be used cautiously and with frequent monitoring of potassium and renal function.

---

### Effects of eplerenone versus losartan in patients with low-renin hypertension [^1161sPx3]. American Heart Journal (2005). Low credibility.

Background

Sodium retention and volume expansion, mediated in part by aldosterone, are prominent features in low-renin hypertension. Agents that block aldosterone at its receptor sites, therefore, should have significant clinical benefit in patients with low-renin hypertension.

Methods

This 16-week, multicenter, double-blind, active-controlled, parallel-group, titration-to-effect trial compared the blood pressure and neurohumoral responses of the selective aldosterone blocker eplerenone (100–200 mg/d; n = 86) with those of the angiotensin receptor blocker losartan (50–100 mg/d; n = 82) in patients with low-renin hypertension (active renin ≤ 25 pg/mL [≤ 42.5 mU/L]). Patients with diastolic blood pressure ≥ 90 mm Hg after 8 weeks of monotherapy received add-on therapy with hydrochlorothiazide 12.5 to 25 mg daily.

Results

After 8 weeks of therapy, eplerenone reduced blood pressure to a greater extent than losartan (systolic blood pressure -15.8 vs -10.1 mm Hg, P = 0.017; diastolic blood pressure -9.3 vs -6.7 mm Hg, P = 0.05). After 16 weeks of therapy, significantly fewer eplerenone-treated patients (32.5%) than losartan-treated patients (55.6%) required add-on hydrochlorothiazide as allowed per protocol for blood pressure control (P = 0.003). Eplerenone consistently reduced blood pressure regardless of baseline active plasma renin levels whereas losartan reduced blood pressure more effectively in patients with higher baseline active renin levels. There were no differences between treatments in adverse events (reported by 62.8% of eplerenone patients and by 72.0% of losartan patients).

Conclusions

These data show that eplerenone was more effective than losartan in reducing blood pressure in patients with low-renin hypertension. Further studies evaluating the efficacy of eplerenone in difficult-to-treat or resistant hypertension are needed.

---

### KDOQI US commentary on the 2009 KDIGO clinical practice guideline for the care of kidney transplant recipients [^117WnsVj]. American Journal of Kidney Diseases (2010). Medium credibility.

KDIGO Chapter 16 — Hypertension in kidney transplant recipients recommends measuring blood pressure at each clinic visit (1C) and suggests maintaining blood pressure at < 130 mm Hg systolic and < 80 mm Hg diastolic if ≥ 18 years of age, and < 90th percentile for sex, age, and height if < 18 years old (2C). To treat hypertension (Not Graded), use any class of antihypertensive agent, monitor closely for adverse effects and drug–drug interactions, and when urine protein excretion is ≥ 1 g/d for ≥ 18 years old and ≥ 600 mg/m²/24 h for < 18 years old, consider an ACE-I or an ARB as first-line therapy.

---

### Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension [^114en6oJ]. Hypertension Research (2019). Medium credibility.

Introduction

Aldosterone acts on mineralocorticoid receptors (MRs) on renal tubular epithelial cells to regulate electrolyte levels and blood fluid volume by promoting sodium reabsorption and urinary potassium (K +) excretion. Therefore, increasing aldosterone levels have been associated with an increased incidence and severity of hypertension. Additionally, aldosterone has been linked with the development and progression of a number of comorbidities associated with hypertension, including endothelial dysfunction, left ventricular hypertrophy, chronic kidney disease, heart failure, stroke, and obstructive sleep apnea. As a result, agents that block the action of aldosterone at MRs have therapeutic activity in a number of conditions, such as hypertension, heart failure, and microalbuminuria.

Existing MR blockers, including spironolactone and eplerenone, have therapeutic utility as add-on therapies for treatment-resistant hypertension. However, the use of these agents is associated with adverse drug reactions that limit their usefulness in clinical practice. Spironolactone has low MR-binding specificity, leading to treatment-related adverse effects, such as sex hormone-related events. Eplerenone has higher MR-binding specificity than was observed for spironolactone, but is still contraindicated in some patients with renal dysfunction.

Esaxerenone is a novel nonsteroidal oral MR blocker with BP-lowering activity. Recently, published phase 1 and phase 2 clinical studies have shown that esaxerenone effectively lowers BP and is well-tolerated. However, there are currently no data on the longer-term efficacy and safety of esaxerenone.

Calcium channel blockers (CCBs) and renin–angiotensin system (RAS) inhibitors are recommended as first-line treatment options for patients with hypertension according to the Japanese Society of Hypertension guidelines (JSH2014). MR blockers are often recommended as an add-on therapy and are likely to be coadministered with CCBs or RAS inhibitors as second- or third-line treatments. The combination of eplerenone with RAS inhibitors has recently been suggested as a potential treatment option in patients with hypertension and chronic kidney disease, especially in whom salt intake is high.

To generate evidence relevant to the usage of esaxerenone in current clinical settings, this phase 3 clinical study investigated the antihypertensive effects of esaxerenone either as a monotherapy or in combination with a CCB or RAS inhibitor and administered for 28 or 52 weeks in Japanese patients with essential hypertension.

---

### Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: association of British clinical diabetologists and the renal association UK guideline update 2021 [^113BxHVp]. BMC Nephrology (2022). Medium credibility.

Blood pressure lowering agents

In people with type 2 diabetes and CKD, three or more blood pressure agents are frequently required. There is increasing emphasis on individualisation of therapy. Eventually, the choice of agent is less important than the actual reduction in blood pressure that is achieved. There is little evidence to support the use of any particular agent in controlling blood pressure in CKD, nor are there any data to suggest the choice of second- or third-line medications. The exception to this rule is the use of ACEIs or ARBs in people with CKD who have proteinuria. ACEIs and ARBs have each been shown to be effective in delaying disease progression in people with type 2 diabetes who have microalbuminuria or established diabetic nephropathy. There is a need to escalate to the maximal doses of ACEI or ARB in people who have diabetes and albuminuria before moving on to additional agents in order to achieve the required blood pressure targets. However, there is no evidence that these agents are effective in the primary prevention of diabetic nephropathy. The use of ACEIs or ARBs in people with type 2 diabetes reduces microalbuminuria and retards the progressive loss of renal function. ARBs are said to provide renoprotection over and above their blood pressure lowering effect and short-term albuminuria reduction, and they are said to have a long-term favourable effect on renal prognosis (Fig. 2).

Fig. 2
Sick day rule

Adherence with therapy

Non-adherence to antihypertensive treatment is common, with over 50% of people with apparent treatment resistance being non-adherent. This is especially so in those who are on multiple anti-hypertensive and other medications. Urine antihypertensive drug monitoring may help management of these individuals. Therefore, it is important to assess adherence especially in those not achieving blood pressure control despite taking 3 or more antihypertensive agents in optimum doses.

---

### Quinapril hydrochloride (Accupril) [^112JQj9q]. FDA (2025). Medium credibility.

Hypertension:

Single doses of 20 mg of ACCUPRIL provide over 80% inhibition of plasma ACE for 24 hours. Inhibition of the pressor response to angiotensin I is shorter-lived, with a 20 mg dose giving 75% inhibition for about 4 hours, 50% inhibition for about 8 hours, and 20% inhibition at 24 hours. With chronic dosing, however, there is substantial inhibition of angiotensin II levels at 24 hours by doses of 20–80 mg.

Administration of 10 to 80 mg of ACCUPRIL to patients with mild to severe hypertension results in a reduction of sitting and standing blood pressure to about the same extent with minimal effect on heart rate. Symptomatic postural hypotension is infrequent although it can occur in patients who are salt-and/or volume-depleted (see WARNINGS). Antihypertensive activity commences within 1 hour with peak effects usually achieved by 2 to 4 hours after dosing. During chronic therapy, most of the blood pressure lowering effect of a given dose is obtained in 1–2 weeks. In multiple-dose studies, 10–80 mg per day in single or divided doses lowered systolic and diastolic blood pressure throughout the dosing interval, with a trough effect of about 5–11/3–7 mm Hg. The trough effect represents about 50% of the peak effect. While the dose-response relationship is relatively flat, doses of 40–80 mg were somewhat more effective at trough than 10–20 mg, and twice daily dosing tended to give a somewhat lower trough blood pressure than once daily dosing with the same total dose. The antihypertensive effect of ACCUPRIL continues during long-term therapy, with no evidence of loss of effectiveness.

Hemodynamic assessments in patients with hypertension indicate that blood pressure reduction produced by quinapril is accompanied by a reduction in total peripheral resistance and renal vascular resistance with little or no change in heart rate, cardiac index, renal blood flow, glomerular filtration rate, or filtration fraction.

Use of ACCUPRIL with a thiazide diuretic gives a blood-pressure lowering effect greater than that seen with either agent alone.

In patients with hypertension, ACCUPRIL 10–40 mg was similar in effectiveness to captopril, enalapril, propranolol, and thiazide diuretics.

Therapeutic effects appear to be the same for elderly (≥ 65 years of age) and younger adult patients given the same daily dosages, with no increase in adverse events in elderly patients.

---

### Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: association of British clinical diabetologists and the renal association UK guideline update 2021 [^1123w2xi]. BMC Nephrology (2022). Medium credibility.

Recommendations (Table 2)

Despite improvements in prognosis, diabetic nephropathy in people with type 1 diabetes remains a major cause of end-stage renal disease. The onset of micro- and macroalbuminuria in people with type 1 diabetes heralds not only an increased risk of renal disease, but also an increased risk of cardiovascular disease. Early prospective studies suggested that around 30–50% of people with type 1 diabetes will develop microalbuminuria, in whom a 6% increase in risk of coronary heart disease is seen per 5 mg increase in 24-h albumin excretion rate (AER). The natural history of diabetic nephropathy in people with type 1 diabetes has, however, changed over the past 4 decades. Studies in the 1970s and 1980s suggested that progression to end-stage kidney disease in people with macroalbuminuria would occur within 7 years. More recent follow-up data of significant numbers of people with type 1 diabetes suggest that end-stage kidney disease occurs in around 3% of people who have had diabetes for 10 years and in around 8% of people who have had diabetes for 30 years.

Table 2
Recommendations for people with type 1 diabetes

a We suggest a target upright blood pressure in younger adults of 120/80 mmHg and 140/90 mmHg for those aged over 65 (Grade 2D)

b Between the ages of 30–65 for some people with higher life-time risk through earlier age of onset of type 1 diabetes, it may be appropriate to target a diastolic BP of < 80 mmHg (Grade 2C)

There is a significant body of evidence to suggest that over-activation of the RAAS plays a major role in the pathogenesis of diabetic nephropathy in people with type 1 diabetes. Over-activation of the RAAS is observed in people with type 1 diabetes, even in the absence of diabetic nephropathy. Angiotensin II-mediated increase in intraglomerular pressure appears to be an important mechanism by which renal disease progresses in people with type 1 diabetes who have diabetic nephropathy, and reductions in intraglomerular pressure may ameliorate glomerular injury. Angiotensin II also has mitogenic effects that may lead to mesangial expansion that is characteristic of diabetic nephropathy. Over-activation of the RAAS may be mediated by hyperglycaemia, and blockade of the RAAS may in turn be impaired by hyperglycaemia. RAAS over-activation is also described in people with type 1 diabetes who have glomerular hyperfiltration.

---

### KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD [^113n5rNC]. American Journal of Kidney Diseases (2013). Medium credibility.

KDIGO recommendations for blood pressure management in chronic kidney disease not on dialysis (CKD ND) without diabetes mellitus state: We recommend that non-diabetic adults with CKD ND and urine albumin excretion < 30 mg per 24 hours (or equivalent) whose office blood pressure (BP) is consistently > 140 mm Hg systolic or > 90 mm Hg diastolic be treated with BP-lowering drugs to maintain a BP that is consistently < 140 mm Hg systolic and < 90 mm Hg diastolic; we suggest that when urine albumin excretion is 30 to 300 mg per 24 hours (or equivalent) and office BP is consistently > 130 mm Hg systolic or > 80 mm Hg diastolic, patients be treated with BP-lowering drugs to maintain a BP that is consistently < 130 mm Hg systolic and < 80 mm Hg diastolic; we suggest that for urine albumin excretion > 300 mg per 24 hours (or equivalent) with the same BP thresholds, treatment should also maintain a BP that is consistently < 130 mm Hg systolic and < 80 mm Hg diastolic; we suggest that an angiotensin receptor blocker (ARB) or angiotensin-converting enzyme inhibitor (ACE-I) be used as first-line therapy for 30 to 300 mg per 24 hours albuminuria in whom treatment with BP-lowering drugs is indicated, and we recommend that an ARB or ACE-I be used as first-line therapy when urine albumin excretion is > 300 mg per 24 hours (or equivalent) in whom treatment with BP-lowering drugs is indicated.

---

### Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: results from DAPASALT and DIAMOND [^115BrjdM]. Diabetes, Obesity & Metabolism (2022). Medium credibility.

Aims

To assess the effect of sodium-glucose cotransporter-2 inhibitor dapagliflozin on natriuresis, blood pressure (BP) and volume status in patients with chronic kidney disease (CKD) without diabetes.

Materials and Methods

We performed a mechanistic open-label study (DAPASALT) to evaluate the effects of dapagliflozin on 24-hour sodium excretion, 24-hour BP, extracellular volume, and markers of volume status during a standardized sodium diet (150mmol/d) in six patients with CKD. In parallel, in a placebo-controlled double-blind crossover trial (DIAMOND), we determined the effects of 6weeks of dapagliflozin on markers of volume status in 53 patients with CKD.

Results

In DAPASALT (mean age 65years, mean estimated glomerular filtration rate [eGFR] 39.4 mL/min/1.73m², median urine albumin:creatinine ratio [UACR] 111mg/g), dapagliflozin did not change 24-hour sodium and volume excretion during 2weeks of treatment. Dapagliflozin was associated with a modest increase in 24-hour glucose excretion on Day 4, which persisted at Day 14 and reversed to baseline after discontinuation. Mean 24-hour systolic BP decreased by -9.3 (95% confidence interval [CI] -19.1, 0.4) mmHg after 4days and was sustained at Day 14 and at wash-out. Renin, angiotensin II, urinary aldosterone and copeptin levels increased from baseline. In DIAMOND (mean age 51years, mean eGFR 59.0 mL/min/1.73m², median UACR 608mg/g), compared to placebo, dapagliflozin increased plasma renin (38.5 [95% CI 7.4, 78.8]%), aldosterone (19.1 [95% CI -5.9, 50.8]%), and copeptin levels (7.3 [95% CI 0.1, 14.5] pmol/L).

Conclusions

During a standardized sodium diet, dapagliflozin decreased BP but did not increase 24-hour sodium and volume excretion. The lack of increased natriuresis and diuresis may be attributed to activation of intra-renal compensatory mechanisms to prevent excessive water loss.

---

### Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: association of British clinical diabetologists and the renal association UK guideline update 2021 [^11123w44]. BMC Nephrology (2022). Medium credibility.

RAAS blockade in people with type 2 diabetes without proteinuria

The use of RAAS blockade has significant benefits on cardiovascular and renal end points in people with diabetes, independent of their blood pressure lowering effect, as shown in the Heart Outcomes Prevention Evaluation (HOPE) trial and the European trial on reduction of cardiac events with perindopril in stable coronary artery disease. Whereas most guidelines favour the use of RAAS blockade as first-line treatment for people with diabetes, hypertension and CKD (the American Diabetes Association, the American Society of Hypertension, the International Society of Hypertension), the European Society of Cardiology / European Society of Hypertension guidelines from 2013 and the eighth Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure from 2014 recommend the use of any class of antihypertensive agent in people with diabetes in the absence of proteinuria, but suggest the use of RAAS blockade as first-line treatment only in the presence of proteinuria.

This is based on the findings of 19 randomised controlled trials that enrolled 25,414 participants with diabetes, with a total of 95,910 patient years of follow-up. The results of this study from head-to-head randomised trials of RAAS blockade versus other antihypertensive agents failed to show superiority of RAAS blockade in people with diabetes and no proteinuria, and it suggested that any class of antihypertensive agents can be used in such individuals.

RAAS blockade in people with type 2 diabetes and proteinuria or microalbuminuria

In the UK, NICE guidance suggests offering a low-cost RAAS antagonist to people with CKD and diabetes who have: a UACR of 3 mg/mmol (26.55 mg/g) or more; hypertension and a UACR of 30 mg/mmol (265.49 mg/g) or more; or a UACR of 70 mg/mmol (619.47 mg/g) or more irrespective of hypertension or cardiovascular disease. The favourable effects of RAAS blockade have been seen mainly in placebo-controlled trials and it has been postulated that the benefits of RAAS blockade on renal outcomes was probably as a result of their blood pressure lowering effect. Several major trials have also demonstrated clear benefits of ARB use in people who have diabetic nephropathy.

---

### The effect of renin-angiotensin-aldosterone system inhibitors on continuous and binary kidney outcomes in subgroups of patients with diabetes: a meta-analysis of randomized clinical trials [^112SsJAU]. BMC Nephrology (2022). Medium credibility.

The latest version of the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines for diabetes management in CKD patients were published in late 2020, and it recommends using RAASi as first-line antihypertensives for patients with diabetes, hypertension and albuminuria. These recommendations were based on four placebo-controlled landmark trials of ARBs on patients with different levels of albuminuria. This recommendation is concordant with those of other guidelines, yet it raises some doubts about the robustness of the evidence behind it. The KDIGO guideline supports its recommendation with evidence from trials of ARBs only. Nevertheless, our analysis on continuous outcomes provides moderate evidence on RAASi's ability to reduce albuminuria levels more than active-treatments. Cativo et al. reached a similar conclusion, and highlighted that although the effect is statistically significant, the clinical effect is small. In summary, the evidence behind promoting RAASi as the leading class in protecting the diabetic kidneys may not be as robust as commonly believed. The findings of this study suggest that the most important factor for preventing and managing diabetic nephropathy is lowering BP levels, which could be of higher significance than the class of the antihypertensive used to lower BP.

Protecting the diabetic kidneys is not exclusive to antihypertensives, as some novel classes claimed their positions in the competition towards protecting diabetic patients from kidney disease using different mechanisms. For example, the mineralocorticoid receptor antagonist (finerenone) is being evaluated in a large RCT (FIDELIO-DKD), with some preliminary promising results. The new antihyperglycemic agents from the sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors class have also shown protective effects against progression of CKD, with reductions of mortality rates when used in combination with RAASi. Sacubitril/valsartan have shown preservation effects of kidney function in older patients with heart failure, and its role in the management of diabetic nephropathy is to be evaluated. Taking the collective adverse events of these agents into consideration, the prescriber today has more options to consider to reduce the progression of diabetic kidney disease. A prescription that combines these agents with a proper antihypertensive could be viewed as the recipe of kidney protection in patients with diabetes. Nevertheless, more research studies need to be carried out to prove the safety and efficacy of such combinations.

---

### Hypertension Canada's 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children [^115guxTh]. The Canadian Journal of Cardiology (2020). High credibility.

Regarding diagnostic investigations for primary aldosteronism, more specifically with respect to plasma aldosterone-to-renin ratio, initial testing, HC 2020 guidelines recommend to obtain plasma aldosterone and plasma renin activity or renin mass/concentration as follows:

- in the morning after the patient has been ambulatory (sitting, standing, or walking) for at least 2 hours

- patients seated for 5–15 minutes before the blood draw

- with corrected hypokalemia and liberalized sodium intake

- withdraw agents markedly affecting the results (aldosterone antagonists, potassium-sparing and -wasting diuretics) at least 4–6 weeks before testing

- repeat testing 2 weeks after withdrawing medications likely to interfere with test accuracy (β-blockers, centrally acting α-2 agonists, ARBs, ACEis, directly acting renin inhibitors, and dihydropyridine CCBs), if the results are not diagnostic, and if hypertension can be controlled with medications less likely to affect testing (slow-release verapamil, diltiazem, hydralazine, prazosin, doxazosin, and terazosin)

- recognize that false positive results might occur with direct renin mass/concentration if the patient is a female using an oral contraceptives; discontinue oral contraceptives for 1 month before testing if possible, or alternately, measure plasma renin activity instead.

---

### 2025 AHA / ACC / AANP / AAPA / ABC / ACCP / ACPM / AGS / AMA / ASPC / NMA / PCNA / SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^1114EEZM]. Hypertension (2025). High credibility.

Secondary hypertension — primary aldosteronism: Prevalence is 5%–25%. Indications include resistant hypertension, hypertension with hypokalemia (spontaneous or diuretic induced), muscle cramps or weakness, incidentally discovered adrenal mass, obstructive sleep apnea, and family history of early-onset hypertension or stroke. Physical findings include arrhythmias (with hypokalemia), especially AF. Screening tests include electrolytes (including sodium and potassium) and plasma aldosterone/renin activity ratio with correction of hypokalemia and withdrawal of MRA for 4–6 wk. Confirmatory testing options include oral sodium loading test (with 24-h urine aldosterone), IV saline infusion test with plasma aldosterone at 4 h of infusion, or captopril suppression test (in patients not on ACEI or ARB treatment), plus adrenal CT scan and adrenal vein sampling.

---

### Hypertension in chronic kidney disease-treatment standard 2023 [^115TfUpd]. Nephrology, Dialysis, Transplantation (2023). Medium credibility.

Hypertension is very common and remains often poorly controlled in patients with chronic kidney disease (CKD). Accurate blood pressure (BP) measurement is the essential first step in the diagnosis and management of hypertension. Dietary sodium restriction is often overlooked, but can improve BP control, especially among patients treated with an agent to block the renin-angiotensin system. In the presence of very high albuminuria, international guidelines consistently and strongly recommend the use of an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker as the antihypertensive agent of first choice. Long-acting dihydropyridine calcium channel blockers and diuretics are reasonable second- and third-line therapeutic options. For patients with treatment-resistant hypertension, guidelines recommend the addition of spironolactone to the baseline antihypertensive regimen. However, the associated risk of hyperkalemia restricts the broad utilization of spironolactone in patients with moderate-to-advanced CKD. Evidence from the CLICK (Chlorthalidone in Chronic Kidney Disease) trial indicates that the thiazide-like diuretic chlorthalidone is effective and serves as an alternative therapeutic opportunity for patients with stage 4 CKD and uncontrolled hypertension, including those with treatment-resistant hypertension. Chlorthalidone can also mitigate the risk of hyperkalemia to enable the concomitant use of spironolactone, but this combination requires careful monitoring of BP and kidney function for the prevention of adverse events. Emerging agents, such as the non-steroidal mineralocorticoid receptor antagonist ocedurenone, dual endothelin receptor antagonist aprocitentan and the aldosterone synthase inhibitor baxdrostat offer novel targets and strategies to control BP better. Larger and longer term clinical trials are needed to demonstrate the safety and efficacy of these novel therapies in the future. In this article, we review the current standards of treatment and discuss novel developments in pathophysiology, diagnosis, outcome prediction and management of hypertension in patients with CKD.

---

### Eprosartan mesylate and hydrochlorothiazide (teveten HCT) [^112VB3LL]. FDA (2012). Low credibility.

Pharmacodynamics and Clinical Effects

Eprosartan: Eprosartan inhibits the pharmacologic effects of angiotensin II infusions in healthy adult men. Single oral doses of eprosartan from 10 mg to 400 mg have been shown to inhibit the vasopressor, renal vasoconstrictive and aldosterone secretory effects of infused angiotensin II with complete inhibition evident at doses of 350 mg and above. Eprosartan inhibits the pressor effects of angiotensin II infusions. A single oral dose of 350 mg of eprosartan inhibits pressor effects by approximately 100% at peak, with approximately 30% inhibition persisting for 24 hours. The absence of angiotensin II AT1agonist activity has been demonstrated in healthy adult men. In hypertensive patients treated chronically with eprosartan, there was a twofold rise in angiotensin II plasma concentration and a twofold rise in plasma renin activity, while plasma aldosterone levels remained unchanged. Serum potassium levels also remained unchanged in these patients. Achievement of maximal blood pressure response to a given dose in most patients may take 2 to 3 weeks of treatment. Onset of blood pressure reduction is seen within 1 to 2 hours of dosing with few instances of orthostatic hypotension. Blood pressure control is maintained with once- or twice-daily dosing over a 24-hour period. Discontinuing treatment with eprosartan does not lead to a rapid rebound increase in blood pressure. There was no change in mean heart rate in patients treated with eprosartan in controlled clinical trials. Eprosartan increases mean effective renal plasma flow (ERPF) in salt-replete and salt-restricted normal subjects. A dose-related increase in ERPF of 25% to 30% occurred in salt-restricted normal subjects, with the effect plateauing between 200 mg and 400 mg doses. There was no change in ERPF in hypertensive patients and patients with renal insufficiency on normal salt diets. Eprosartan did not reduce glomerular filtration rate in patients with renal insufficiency or in patients with hypertension, after 7 days and 28 days of dosing, respectively. In hypertensive patients and patients with chronic renal insufficiency, eprosartan did not change fractional excretion of sodium and potassium. Eprosartan (1200 mg once daily for 7 days or 300 mg twice daily for 28 days) had no effect on the excretion of uric acid in healthy men, patients with essential hypertension or those with varying degrees of renal insufficiency. There were no effects on mean levels of fasting triglycerides, total cholesterol, HDL cholesterol, LDL cholesterol or fasting glucose.

---

### Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers [^116Wm6Zm]. Hypertension Research (2023). Medium credibility.

Introduction

Aldosterone is a key component of the renin-angiotensin-aldosterone system (RAAS). It is produced in the zona glomerulosa of the adrenal cortex in response to angiotensin II, high extracellular potassium concentration, and adrenocorticotropic hormone (ACTH). Aldosterone is involved in the regulation of fluid and electrolyte homeostasis via activation of the mineralocorticoid receptor (MR) on various tissues, which causes vasoconstriction of vascular smooth muscle and increased water and sodium absorption by the kidneys. The rate-limiting enzyme in the synthetic pathway of aldosterone is aldosterone synthase (also known as CYB11B2).

Current first-line treatments for hypertension include diuretics, angiotensin-converting enzyme (ACE) inhibitors, and/or angiotensin receptor blockers (ARBs). However, aldosterone breakthrough can occur with long-term treatment with ACE inhibitors and ARBs. The preferred agents for treating primary aldosteronism and treatment-resistant hypertension are MR antagonists (spironolactone and eplerenone), although long-term use of spironolactone is associated with a greater risk of gynecomastia and sexual dysfunction due to off-target effects. Eplerenone does not have these same side effects but is less potent than spironolactone.

Chronically elevated aldosterone levels can lead to hypokalemia, sodium reabsorption, and fluid retention, resulting in increased blood pressure (BP). Furthermore, inflammation, end organ damage, fibrosis, cardiovascular events (e.g. ventricular hypertrophy), and adverse renal events (e.g. increased urinary albumin excretion, progression of renal failure) can occur with increased aldosterone levels independently of BP. The association between high plasma aldosterone and decreased long-term survival has been demonstrated in patients with congestive heart failure, acute myocardial infarction (MI), and coronary artery disease outside the setting of acute MI or heart failure. Thus, aldosterone synthase inhibition may be a promising therapeutic strategy for BP control and mitigation of end organ damage.

Baxdrostat (CIN-107) is a highly potent, selective, and competitive small molecule inhibitor of aldosterone synthase, as demonstrated by preclinical and first-in-human clinical studies. In vitro, baxdrostat exhibited a high selectivity ratio for aldosterone synthase compared to the highly homologous enzyme responsible for cortisol synthesis 11β-hydroxylase (CYP11B1). In vivo, nonhuman primate pharmacology characterization showed that baxdrostat blunted aldosterone production while having no effect on cortisol levels.

---

### American association of clinical endocrinology consensus statement: comprehensive type 2 diabetes management algorithm-2023 update [^116eXTzN]. Endocrine Practice (2023). High credibility.

Hypertension evaluation for resistant cases and primary hyperaldosteronism — screening and treatment guidance — states that patients should be screened if they have resistant HTN (> 140/90 mm Hg) on ≥ 3 medications, including a maximum-dose diuretic. A mineralocorticoid receptor antagonist (MRA) (eg, eplerenone, spironolactone) is the rational choice for medical management of primary hyperaldosteronism and can be considered for resistant HTN in persons with T2D. More frequent laboratory monitoring of potassium and kidney function should be performed when an ACEi or ARB is combined with an MRA.

---

### Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies [^1137dHBp]. The Lancet: Diabetes & Endocrinology (2018). Medium credibility.

Aldosterone secretion is normally suppressed when renin is low, unless there is autonomous aldosterone production — eg, from an aldosterone-producing adenoma. This aldosterone suppression is apparent during acute salt loading, in cross-sectional studies of dietary sodium intake, in some of the rare monogenic causes of hypertension, and in patients whose low-renin hypertension is due to derivatives of naturally occurring mineralocorticoids. Unsuppressed plasma aldosterone values raise suspicion that they are the driver of salt retention. The paucity of patients with low plasma aldosterone and low plasma renin in our study is consistent with aldosterone having a primary role in many patients with resistant hypertension. However, none of the patients, even one whose hypertension was cured by removal of a 7 mm aldosterone-producing adenoma, exhibited the triad of spontaneous hypokalaemia, completely suppressed renin, and plasma aldosterone of more than 550 pmol/L that is currently required for diagnosis of primary aldosteronism if a suppression test (the alternative method of diagnosis) is to be avoided.

The absence of this triad could be anticipated from the eligibility criteria for PATHWAY-2. Yet, despite our exclusion of patients with known or suspected secondary hypertension, even the more conservative of our estimates for primary aldosteronism frequency (10%) exceeds the prevalence of 99 (5.9%) of 1672 unselected patients with hypertension who were recruited from primary care (like most patients in PATHWAY-2), and is similar to the 126 (11.2%) of 1125 newly diagnosed patients referred to specialist clinics. Our estimate was enabled by the recent prospective comparison of confirmatory tests for primary aldosteronism, showing that a post-captopril ARR greater than 60.94 pmol/L −1 per mU/L −1 is equivalent to a positive saline suppression test, because all patients at entry to PATHWAY-2 were already treated with maximum-tolerated doses of RAS blocker. At most, nine patients might have been excluded from PATHWAY-2 if entry had (implausibly) required two ARR estimations in all screened patients and follow-up confirmatory tests when ARR was higher than 60.94 pmol/L −1 per mU/L −1.

---

### Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension [^111tKewN]. Journal of Human Hypertension (2010). Low credibility.

Eplerenone, a selective aldosterone blocker, has become clinically available in Japan since 2007. It has been reported that eplerenone has a potential antihypertensive effect, with a profile slightly different from that of spironolactone, and has fewer adverse reactions, suggesting that it may become a first-line treatment for hypertension. However, clinical data on hypertensive patients in Japan are lacking for eplerenone. In this study, we explored the clinical efficacy of eplerenone when it is added to an angiotensin-converting enzyme (ACE) inhibitor or a long-acting calcium channel blocker (CCB) in 68 (31 males, 37 females) Japanese patients with essential hypertension. After adding 50 mg of eplerenone to their basal treatment, blood pressure was significantly reduced at 4 weeks, and further reduced after 24 weeks of eplerenone treatment. Urinary albumin excretion decreased significantly after 24 weeks. There were no significant differences in general biochemical test values or electrolytes, but fasting serum triglycerides were significantly decreased after eplerenone treatment. The serum potassium level showed no significant change during treatment. There were no significant correlations between plasma renin activity or plasma aldosterone concentration (PAC) before eplerenone treatment and blood pressure after eplerenone treatment, showing that the antihypertensive effect of eplerenone is not affected by the patient's renin profile or pretreatment PAC values. Eplerenone was also effective in hypertensive patients with metabolic syndrome. In conclusion, eplerenone, when coadministered with an ACE inhibitor or a long-acting CCB, caused an extremely beneficial antihypertensive effect in Japanese patients with essential hypertension, without few clinically important adverse events.

---

### Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism [^111kET4s]. Circulation (2004). Low credibility.

Background

Recent studies suggest that aldosterone may impair endothelium-dependent vascular function through suppression of nitric oxide formation. Assessments of forearm blood flow or arterial compliance suggest a similar effect in humans. The present study was designed to determine whether chronic aldosterone excess in subjects with resistant hypertension impairs endothelium-dependent vascular reactivity as indexed by direct assessment of brachial artery flow-mediated dilation (FMD).

Methods and Results

Consecutive subjects (n = 80) with resistant hypertension were prospectively evaluated with an early-morning ratio of plasma aldosterone to plasma renin activity and 24-hour urinary aldosterone and sodium. Changes in brachial artery diameter during reactive hyperemia were measured by high-resolution ultrasound. Hyperaldosteronism was diagnosed on the basis of a renin activity < 1.0 ng x mL(-1) x h(-1), urinary aldosterone > 12 microg/24 h, and urinary sodium > 200 mEq/24 h. FMD was significantly lower in 36 subjects with hyperaldosteronism (1.8 ± 1.3% versus 3.9 ± 1.9% from baseline; P < 0.0001) compared with the 44 subjects without hyperaldosteronism. FMD was negatively and significantly correlated with plasma aldosterone (r = -0.38, P = 0.0006), 24-hour urinary aldosterone (r = -0.49, P < 0.0001), and ratio of plasma aldosterone to plasma renin activity (r = -0.43, P < 0.0001) but was independent of blood pressure, age, and body mass index. In 30 subjects, 3 months of treatment with spironolactone significantly increased FMD (2.5 ± 1.7 versus 6.0 ± 2.0%; P < 0.0001) independently of blood pressure change.

Conclusions

These data demonstrate a strong association between aldosterone excess and impaired endothelial function in human subjects as indexed by flow-mediated arterial vasodilation. These results suggest that chronic aldosteronism may have a blood pressure-independent effect on cardiovascular disease progression in subjects with resistant hypertension.

---

### Abstract, closing summary, and table of contents for laragh's 25 lessons in pathophysiology and 12 clinical pearls for treating hypertension [^113KSLFs]. American Journal of Hypertension (2001). Low credibility.

These 25 lessons 1) review the roles of plasma renin levels for causing malignant and most essential hypertension and their related vascular injuries (heart attack, heart failure, kidney failure and stroke); 2) review how antihypertensive anti-R drugs that block renin activity (beta blockers, the first converting enzyme inhibitor from venom, and the first angiotensin receptor blocker) were used to reveal plasma renin involvement in the hypertension of medium and high renin patients and to show; 3) that the 30% with low renin essential hypertension do not respond to R drugs, are not prone to heart attack or stroke, and BP is corrected instead by the natriuretic anti-V drugs (diuretics, spironolactone, CCB, alpha blockers); 4) thus, all hypertensives can be divided into R patients who have too much renin vasoconstriction or V patients who instead have predominant sodium-volume mediation. Furthermore, all antihypertensive drug classes can be divided into R drugs that block the renin factor, or V drugs that reduce body sodium volume; 5) these findings document our conception of two biochemically and physiologically different final factors that sustain all BP in which the sodium-volume factor continuously sustains cardiac output and flow while plasma renin-angiotensin sets total peripheral resistance (TPR), which, within the Poiseuille Equation (BP = cardiac output [CO] x TPR) describes our [Na+-volume x renin-angiotensin vasoconstriction] model that supports all normotension or hypertension; 6) in this light, we designed a visit-by-visit method for treating untreated hypertensives using the ambient plasma renin level and BP responses to guide primary drug therapy against either the V or R factor; and 7) for also correcting nonresponders receiving multiple drugs where renin testing correctly guides addition or subtraction of drugs depending on whether the test indicates unresponsiveness due to a reactive sodium-volume excess, or to lack of effectiveness of an R drug in a V patient or of a V drug in an R patient, or from large reactive increases in renin that override the R drug, calling for strengthening the R and/or removing V drugs. This objective, biochemically based method results in effective longterm BP control of nearly all patients using fewer, but the correct drug(s) for each individual.

---

### Primary aldosteronism [^111KrBWa]. American Family Physician (2023). High credibility.

Regarding screening and diagnosis for primary aldosteronism, more specifically with respect to indications for testing, hypertension, AAFP 2023 guidelines recommend to measure plasma aldosterone concentration and plasma renin levels simultaneously in the initial case detection for PA, recognizing that aldosterone elevation with suppressed renin levels identifies patients with potential PA.

---

### KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD [^115Ax8VJ]. American Journal of Kidney Diseases (2014). Medium credibility.

Prevention of chronic kidney disease (CKD) progression — blood pressure (BP) and renin-angiotensin-aldosterone system (RAAS) interruption — includes the following on-page recommendations. "Individualize BP targets and agents according to age, coexistent cardiovascular disease and other comorbidities, risk of progression of CKD, presence or absence of retinopathy (in CKD patients with diabetes), and tolerance of treatment" (Not Graded). "Inquire about postural dizziness and check for postural hypotension regularly when treating CKD patients with BP-lowering drugs" (Not Graded). "Tailor BP treatment regimens in elderly patients with CKD" with gradual escalation and attention to adverse events (Not Graded). For adults with "urine albumin excretion < 30 mg/24 hours (or equivalent)" and office BP "consistently > 140 mm Hg systolic or > 90 mm Hg diastolic", "We recommend" BP-lowering drugs to maintain BP "consistently ≤ 140 mm Hg systolic and ≤ 90 mm Hg diastolic" (1B). For adults with "urine albumin excretion of ≥ 30 mg/24 hours (or equivalent)" and office BP "consistently > 130 mm Hg systolic or > 80 mm Hg diastolic", "We suggest" treatment to maintain BP "consistently ≤ 130 mm Hg systolic and ≤ 80 mm Hg diastolic" (2D). Pharmacotherapy is specified: "We suggest that an ARB or ACE-I be used in diabetic adults with CKD and urine albumin excretion 30–300 mg/24 hours (or equivalent)" (2D), and "We recommend that an ARB or ACE-I be used in both diabetic and non-diabetic adults with CKD and urine albumin excretion ≥ 300 mg/24 hours (or equivalent)" (1B). Combination therapy is addressed: "There is insufficient evidence to recommend combining an ACE-I with ARBs to prevent progression of CKD" (Not Graded). For pediatrics, "We recommend that in children with CKD, BP-lowering treatment is started when BP is consistently above the 90th percentile for age, sex, and height" (1C).

---

### Baxdrostat for uncontrolled and resistant hypertension: rationale and design of the phase 3 clinical trials baxHTN, baxAsia, and bax24 [^1149ir4U]. Hypertension Research (2025). Medium credibility.

Bax24 will complement BaxHTN and BaxAsia, by assessing ambulatory 24-h average SBP. Longitudinal studies conducted in both the general population and patients with hypertension have demonstrated that ambulatory BP provides a more accurate prediction of hypertension outcomes than seated office BP. In patients with controlled seated office BP but elevated ambulatory BP, an increased risk of organ damage and adverse cardiovascular events was observed versus patients with controlled ambulatory BP. Assessing 24-h average SBP and night-time average SBP is also important as BP variability and high nocturnal BP levels are associated with increased cardiovascular risk. This suggests seated office BP and ambulatory BP measurements may be complementary in determining hypertension prognosis.

Historically, hypertension trials for MRAs have focused on patients with rHTN. BaxHTN and BaxAsia broaden the population of patients included to those with uHTN despite ongoing background treatment with two antihypertensive treatments, in addition to those with rHTN. This will highlight the potential beneficial impact of treating uHTN before it becomes resistant and therefore increase the external applicability of their results to a broader population of patients of diverse ethnicities. Bax24 will only enroll patients with rHTN using the highest baxdrostat dose (2 mg) as they are more likely to have aldosterone dysregulation than those with uHTN only. Moreover, patients with rHTN have demonstrated favorable BP responses to MRAs and may therefore derive the largest ambulatory BP decreases with baxdrostat.

BaxHTN, BaxAsia, and Bax24 have been designed to assess the effect of baxdrostat in addition to standard background hypertension therapy, thus maximizing the relevance of their results to clinical practice. Furthermore, placebo use is limited to avoid the risks of uncontrolled BP, and patients are permitted to continue their background antihypertensive treatments. To provide a clear understanding of the long-term safety profile of baxdrostat, the study durations extend to 52 weeks with hyperkalemia (potassium level > 5.0 mmol/L), hyponatremia (sodium level < 135 mmol/L), and hypotension events that require medical intervention included as AEs of special interest.

By recruiting patients from a wide range of countries, this will potentially further our understanding of ASI use in patients of different ethnicities. This includes patients living in Asia who may have a significantly greater risk of aldosterone dysregulation and hypertension-associated adverse cardiovascular events due to higher dietary salt intake and greater salt sensitivity, compared with patients living in countries outside of Asia such as Australia and New Zealand.

---

### 2025 AHA / ACC / AANP / AAPA / ABC / ACCP / ACPM / AGS / AMA / ASPC / NMA / PCNA / SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^111YrF4B]. Hypertension (2025). High credibility.

Resistant hypertension — initial combination therapy and mineralocorticoid receptor antagonist (MRA) use — Antihypertensive drug therapy should start with a combination of an ACEi or ARB, a CCB, and a diuretic. Replacing thiazide-type diuretics (eg, HCTZ or bendroflumethiazide) with thiazide-like diuretics (eg, chlorthalidone and indapamide) may offer additional BP reduction and cardiovascular protection among patients with previous MI or stroke. Randomized controlled trials have shown that addition of spironolactone (25–50 mg/day) as the fourth drug reduced home and 24-hour SBP by 6.6 to 8.7 mm Hg when compared with placebo in patients with resistant hypertension and eGFR < 45 mL/ min/1.73 m²; the reduction in BP was greater than with addition of doxazosin or bisoprolol, and the magnitude of reduction in 24-hour systolic and diastolic BP was greater with spironolactone than clonidine in a separate clinical trial. Nevertheless, 4% to 40% of adults with resistant hypertension cannot tolerate spironolactone due to hyperkalemia or antiandrogenic side effects. For eplerenone, RCTs have not demonstrated reduction of home BP or 24-hour BP at doses between 25 and 100 mg daily when compared with placebo, and effective treatment may require higher dosages; use of nonsteroidal MRA for treating resistant hypertension in patients with moderate to advanced CKD has not been tested in a clinical trial but may be considered in selected patients with close monitoring of serum potassium.

---

### Obesity and hypertension: Obesity Medicine Association (OMA) clinical practice statement (CPS) 2023 [^1137ZVQY]. Obesity Pillars (2023). High credibility.

Increased activation of the renin-angiotensin-aldosterone system (RAAS) — adipose contributions to hypertension: Angiotensinogen is mainly produced by the liver, with variably increased angiotensinogen production by large adipose tissue deposits as well as smaller deposits such as visceral and perivascular adipose tissue, and angiotensinogen levels are increased with obesity. Angiotensinogen is converted into angiotensin I by renin and then to angiotensin II by angiotensin-converting enzyme; angiotensin II is a vasoconstrictor that increases vascular peripheral resistance and increases blood pressure and also stimulates aldosterone release that promotes sodium and water reabsorption by the kidneys; aldosterone can also be produced by adipocytes in patients with obesity. The increase in vascular vasoconstriction, coupled with increased water reabsorption increases blood pressure.

---

### Spironolactone reduces aortic stiffness in patients with resistant hypertension independent of blood pressure change [^115UoRLV]. Journal of the American Heart Association (2021). Medium credibility.

Spironolactone Treatment and Withdrawal of Other Antihypertensive Drugs

All participants were started on spironolactone 25 mg/d in addition to other antihypertensive medications and force‐titrated to 50 mg/d at 4 weeks. After addition of spironolactone, other antihypertensive medications were withdrawn as needed to maintain constant BP. The sequence of withdrawal was as follows: centrally acting agents or vasodilators first, followed by β‐blockers, calcium channel blockers, and renin‐angiotensin system blockers.

BP Measurements

BP was noninvasively measured using a manual brachial mercury sphygmomanometer and an appropriately sized cuff after 5 minutes of rest. During each CMR imaging study, BP measurements were performed twice, before scanning and immediately after completion of scanning; these were performed in the scan room but outside the CMR imaging instrument. The average of 2 readings was recorded and used for analysis. The average pulse pressure (PP) was calculated as the difference in average systolic and average diastolic BP.

Biochemical Testing

Plasma aldosterone concentration (PAC), plasma renin activity (PRA), brain natriuretic peptide, serum potassium, and creatinine levels were measured in the morning between 8and 9with the patient in the upright sitting position. A 24‐hour urine collection for aldosterone, cortisol, sodium, and creatinine was performed. PAC, PRA, and 24‐hour urinary aldosterone was analyzed using liquid chromatography‐tandem mass spectrometry (Mayo Medical Laboratories) with laboratory reference levels as follows: high PAC ≥ 16 ng/dL, high 24‐hour urinary aldosterone ≥ 12 μg/24‐hour, and suppressed PRA < 1 ng/mL per hour.

---

### Autonomic nervous system activity changes in patients with hypertension and overweight: role and therapeutic implications [^111BRC9L]. Cardiovascular Diabetology (2021). Medium credibility.

Catheter-based renal denervation

Catheter-based renal denervation has been explored as a treatment for drug-resistant hypertension. Renal denervation decreased blood pressure and reduced cardiovascular morbidity. As well as the effects on blood pressure, renal denervation has demonstrated a decrease in muscle sympathetic nerve activity with a reduction of SNS-mediated effects such as improved glycaemic control and insulin resistance, and decreased total peripheral resistance. Observed positive effects of renal denervation on the cardiovascular system include reduced arterial stiffness (lower pulse wave velocity), reduced left ventricular mass, improved heart failure symptoms and diastolic function, and increased left ventricular ejection fraction. Heart rate is also significantly reduced through renal denervation. With regards to the effects on the kidney, renal denervation has been shown to reduce renal noradrenaline spill over and plasma renin release. Interestingly, a recent paper showed that a baseline 24-h heart rate above the median (73.5 bpm), suggesting a higher sympathetic activity, predicted greater BP reductions after renal denervation and may allow physicians to select patients likely to respond to the procedure.

Pharmacological strategies

Several pharmacological strategies can be set up to decrease blood pressure, targeting either RAAS (angiotensin converting enzyme inhibitors (ACEis)/angiotensin receptor blockers (ARBs)), cardiac output (β-blockers), peripheral vascular resistance (calcium channel blockers (CCB) or sodium reabsorption (diuretics).

Pharmacological therapies for the management of hypertension via inhibition of the SNS include beta-blockers and imidazoline receptor agonists, targeting beta-adrenergic and imidazoline I 1 receptors, respectively. While ACEis and ARBs act by antagonising the renin–angiotensin–aldosterone system, they appear to have little or no effect on the SNS.

Beta-blockers

Beta-blockers, also indicated for the treatment of heart failure, decrease SNS activation by antagonizing beta-adrenergic receptors, and have potential beneficial effects on cardiac fibrosis. While they reduce SNS activation and cardiovascular outcomes in patients with heart failure and reduced LV ejection fraction, they also have unwanted negative metabolic effects including insulin resistance, dyslipidemia and reduced glycaemic control. They also increase weight gain.

---

### American Association of Clinical Endocrinologists and American college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity [^111E2oUy]. Endocrine Practice (2016). Medium credibility.

Regarding specific circumstances for hypertension, more specifically with respect to patients with obesity, antihypertensive therapy, AACE/ACE 2016 guidelines recommend to initiate RAAS inhibition therapy (ARBs or ACEis) as first-line therapy for BP control in patients with obesity. Consider initiating combination antihypertension therapy with CCBs as second-line therapy.

---

### Telmisartan and amlodipine [^111wysRf]. FDA (2023). Medium credibility.

12.2 Pharmacodynamics

Telmisartan and Amlodipine Tablets

Telmisartan and amlodipine tablets have been shown to be effective in lowering blood pressure. Telmisartan and amlodipine tablet is a combination of two drugs with antihypertensive properties: a dihydropyridine calcium antagonist (calcium ion antagonist or slow-channel blocker), amlodipine besylate, and an angiotensin II receptor blocker, telmisartan.

Both telmisartan and amlodipine lower blood pressure by reducing peripheral resistance but through complementary mechanisms.

Telmisartan

In normal volunteers, a dose of telmisartan 80 mg inhibited the pressor response to an intravenous infusion of angiotensin II by about 90% at peak plasma concentrations with approximately 40% inhibition persisting for 24 hours.

Plasma concentration of angiotensin II and plasma renin activity (PRA) increased in a dose-dependent manner after single administration of telmisartan to healthy subjects and repeated administration to hypertensive patients. The once-daily administration of up to 80 mg telmisartan to healthy subjects did not influence plasma aldosterone concentrations. In multiple dose studies with hypertensive patients, there were no clinically significant changes in electrolytes (serum potassium or sodium), or in metabolic function (including serum levels of cholesterol, triglycerides, HDL, LDL, glucose, or uric acid).

---

### Obesity-related hypertension: epidemiology, pathophysiology, and clinical management [^114dQS1r]. American Journal of Hypertension (2010). Low credibility.

The prevalence of obesity, including childhood obesity, is increasing worldwide. Weight gain is associated with increases in arterial pressure, and it has been estimated that 60–70% of hypertension in adults is attributable to adiposity. Centrally located body fat, associated with insulin resistance and dyslipidemia, is a more potent determinant of blood pressure elevation than peripheral body fat. Obesity-related hypertension may be a distinct hypertensive phenotype with distinct genetic determinants. Mechanisms of obesity-related hypertension include insulin resistance, sodium retention, increased sympathetic nervous system activity, activation of renin-angiotensin-aldosterone, and altered vascular function. In overweight individuals, weight loss results in a reduction of blood pressure, however, this effect may be attenuated in the long term. An increasing number of community-based programs (including school programs and worksite programs) are being developed for the prevention and treatment of obesity. Assessment and treatment of the obese hypertensive patient should address overall cardiovascular disease (CVD) risk. There are no compelling clinical trial data to indicate that any one class of antihypertensive agents is superior to others, and in general the principles of pharmacotherapy for obese hypertensive patients are not different from nonobese patients. Future research directions might include: (i) development of effective, culturally sensitive strategies for the prevention and treatment of obesity; (ii) clinical trials to identify the most effective drug therapies for reducing CVD in obese, hypertensive patients; (iii) continued search for the genetic determinants of the obese, hypertensive phenotype.

---

### What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment? [^112UvZU5]. Cardiovascular Diabetology (2012). Low credibility.

Hypertension has a major associated risk for organ damage and mortality, which is further heightened in patients with prior cardiovascular (CV) events, comorbid diabetes mellitus, microalbuminuria and renal impairment. Given that most patients with hypertension require at least two antihypertensives to achieve blood pressure (BP) goals, identifying the most appropriate combination regimen based on individual risk factors and comorbidities is important for risk management. Single-pill combinations (SPCs) containing two or more antihypertensive agents with complementary mechanisms of action offer potential advantages over free-drug combinations, including simplification of treatment regimens, convenience and reduced costs. The improved adherence and convenience resulting from SPC use is recognised in updated hypertension guidelines. Despite a wide choice of SPCs for hypertension treatment, clinical evidence from direct head-to-head comparisons to guide selection for individual patients is lacking. However, in patients with evidence of renal disease or at greater risk of developing renal disease, such as those with diabetes mellitus, microalbuminura and high-normal BP or overt hypertension, guidelines recommend renin-angiotensin system (RAS) blocker-based combination therapy due to superior renoprotective effects compared with other antihypertensive classes. Furthermore, RAS inhibitors attenuate the oedema and renal hyperfiltration associated with calcium channel blocker (CCB) monotherapy, making them a good choice for combination therapy. The occurrence of angiotensin-converting enzyme (ACE) inhibitor-induced cough supports the use of angiotensin II receptor blockers (ARBs) for RAS blockade rather than ACE inhibitors. In this regard, ARB-based SPCs are available in combination with the diuretic, hydrochlorothiazide (HCTZ) or the calcium CCB, amlodipine. Telmisartan, a long-acting ARB with preferential pharmacodynamic profile compared with several other ARBs, and the only ARB with an indication for the prevention of CV disease progression, is available in two SPC formulations, telmisartan/HCTZ and telmisartan/amlodipine. Clinical studies suggest that in CV high-risk patients and those with evidence of renal disease, the use of an ARB/CCB combination may be preferred to ARB/HCTZ combinations due to superior renoprotective and CV benefits and reduced metabolic side effects in patients with concomitant metabolic disorders. However, selection of the most appropriate antihypertensive combination should be dependent on careful review of the individual patient and appropriate consideration of drug pharmacology.

---

### Effect of hydrochlorothiazide in addition to telmisartan / amlodipine combination for treating hypertensive patients uncontrolled with telmisartan / amlodipine: a randomized, double-blind study [^112DUbAJ]. Hypertension Research (2017). Low credibility.

Introduction

According to the Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014), it is estimated that ∼43 million people are affected by hypertension in Japan. It is concerning that the number of people with hypertension may continue to increase with aging of the population. In a survey of 4000 hypertensive subjects, the proportion with controlled blood pressure was 34.9% in 2006, and this improved to 50% in 2009; however, blood pressure control remains inadequate. Another survey conducted in 3000 subjects in 1994, 2001 and 2010 showed that the mean number of prescribed agents per patient increased gradually from 1.64 in 1994 to 1.79 in 2001 and to 2.04 in 2010. For many patients, a combination of two or more treatments, or an increased dose of combination therapy, is required to achieve any antihypertensive effect.

Angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme inhibitors, calcium channel blockers (CCBs) and diuretics are first-line drugs for the management of hypertension.CCBs and ARBs lower blood pressure by vasodilating effects. Diuretics increase the excretion of excess water and sodium, thereby decreasing peripheral vascular resistance.

Among these first-line drugs, ARB/CCB combination therapy is widely used for hypertensive patients as a second-line treatment. In a phase III study, a combined antihypertension treatment containing 80 mg of the ARB telmisartan and 5 mg of the CCB amlodipine (Micamlo combination tablets BP; Nippon Boehringer Ingelheim) reduced diastolic blood pressure (DBP) to ≤ 90 mm Hg in 70.1% of patients compared with 41.5% of patients taking telmisartan monotherapy (data on file, Nippon Boehringer Ingelheim, Tokyo, Japan).

---

### Primary aldosteronism: an endocrine society clinical practice guideline [^115bXNhZ]. The Journal of Clinical Endocrinology and Metabolism (2025). High credibility.

Regarding diagnostic investigations for primary aldosteronism, more specifically with respect to plasma aldosterone-to-renin ratio, initial testing, ES 2025 guidelines recommend to consider obtaining serum/plasma aldosterone concentration and plasma renin (concentration or activity), with determination of the aldosterone-to-renin ratio, to screen for PA in patients with hypertension.

---

### 2024 ESC guidelines for the management of elevated blood pressure and hypertension [^113u9ZD3]. European Heart Journal (2024). High credibility.

Regarding medical management for hypertension, more specifically with respect to choice of antihypertensives, initial therapy, ESC 2024 guidelines recommend to initiate ACEis, ARBs, dihydropyridine CCBs, and diuretics (thiazides and thiazide-like drugs such as chlorthalidone and indapamide) as first-line treatment options to lower BP, given their demonstrated effectiveness in reducing BP and CVD events.

---

### Blood pressure guidelines-where are we now? [^115pucha]. Drug and Therapeutics Bulletin (2008). Low credibility.

In June 2006, the National Institute for Health and Clinical Excellence (NICE) updated its recommendations on the management of patients with hypertension (published in 2004), in light of "significant new data" relating to drug treatment.1,2 The update, published in collaboration with the British Hypertension Society (BHS), recommended first-line use of a calcium-channel blocker or a thiazide-type diuretic in patients aged over 55 years or an ACE inhibitor in those aged under 55 years, and advised that beta-blockers should no longer be used for routine initial therapy.1 Recently published data from England suggest that primary care prescribing has changed in line with this new guideline.3 However, interpretation of the evidence that underpins some of the key recommendations is open to debate, particularly as there are differences from some other major guidelines in the recommendations for first-line therapy. Here we consider the updated NICE guideline, the rationale for its treatment recommendations, and the subsequent change in clinical practice. In particular, we focus on the initial drug management of adults without conditions such as diabetes mellitus or coronary heart disease that would in themselves be a key determinant of management.

---

### Renal autonomic dynamics in hypertension: how can we evaluate sympathetic activity for renal denervation? [^114VPUsy]. Hypertension Research (2024). Medium credibility.

This review explores the various pathophysiological factors influencing antihypertensive effects, involving the regulation of vascular resistance, plasma volume, cardiac function, and the autonomic nervous system, emphasizing the interconnected processes regulating blood pressure (BP). The kidney's pivotal role in BP control and its potential contribution to hypertension is complicated but important to understand the effective mechanisms of renal denervation (RDN), which may be a promising treatment for resistant hypertension. Excessive stimulation of the sympathetic nervous system or the renin-angiotensin-aldosterone system (RAAS) can elevate BP through various physiological changes, contributing to chronic hypertension. Renal sympathetic efferent nerve activation leads to elevated norepinephrine levels and subsequent cascading effects on vasoconstriction, renin release, and sodium reabsorption. RDN reduces BP in resistant hypertension by potentially disrupting sensory afferent nerves, decreasing feedback activation to the central nervous system, and reducing efferent sympathetic nerve activity in the heart and other structures. RDN may also modulate central sympathetic outflow and inhibit renal renin-angiotensin system overactivation. While evidence for RDN efficacy in hypertension is increasing, accurate patient selection becomes crucial, considering complex interactions that vary among patients. This review also discusses methods to evaluate autonomic nerve activity from the golden standard to new potential examination for finding out optimization in stimulation parameters or rigorous patient selection based on appropriate biomarkers.

---

### Effects of estradiol and the angiotensin II receptor blocker irbesartan on vascular function in postmenopausal women [^112cDgvN]. Menopause (2008). Low credibility.

Objective

Estradiol and angiotensin receptor blockers have prominent effects on the renin-angiotensin-aldosterone system. The purpose of this study was to determine whether irbesartan, an angiotensin receptor blocker, has a greater effect on vascular function when combined with estradiol, compared with irbesartan alone, in hypertensive postmenopausal women.

Design

Fifty-one women were studied while off any antihypertensive medications or hormone therapy at baseline and after randomization to one of four treatment arms for 12 weeks: (1) irbesartan and estradiol, (2) irbesartan and placebo, (3) estradiol and placebo, and (4) placebo/placebo. Estradiol and placebo arms served as control groups. Blood pressure, brachial reactivity, aldosterone, insulin, glucose, 24-hour urinary catecholamines, urinary sodium, and creatinine were measured. Fisher's exact test was used for comparison of differences in blood pressure in the treatment arms. Paired t test and analysis of variance were also performed for within- and between-group analysis.

Results

A significantly larger number of women in the irbesartan and estradiol group had a decrease of 5 mm Hg or more in both systolic and diastolic blood pressures (P < 0.05) compared with irbesartan alone group. Forearm vascular reactivity was increased significantly compared with baseline (P < 0.05), and there was a significant decrease in the serum aldosterone level after treatment compared with baseline (P < 0.05) in the irbesartan and estradiol combination group. Fasting glucose and insulin, urinary sodium/creatinine ratio, and catecholamines were similar at each time point.

Conclusions

The results suggest that irbesartan and estradiol, when used in combination, may cause a greater lowering of blood pressure in postmenopausal hypertensive women. This effect may be mediated via increased vasodilation and lower aldosterone levels. These results warrant further testing in larger clinical trials.

---

### Standards of care in diabetes – 2025 [^1125hA23]. Diabetes Care (2025). High credibility.

Regarding specific circumstances for chronic kidney disease, more specifically with respect to patients with diabetes mellitus, renin-angiotensin system inhibitors, ADA 2025 guidelines recommend to monitor for increased serum creatinine and for increased serum potassium levels when ACEis, ARBs, or mineralocorticoid receptor antagonists are used, or for hypokalemia when diuretics are used at routine visits and 7–14 days after initiation or after a dose change.

---

### Hypertension in adults: initial evaluation and management [^113hhZjA]. American Family Physician (2023). High credibility.

Regarding specific circumstances for hypertension, more specifically with respect to patients with CKD, antihypertensives, AAFP 2023 guidelines recommend to initiate an ACEi inhibitor or an ARB as initial treatment in patients with HTN and proteinuric CKD.

---

### Editor's choice-European Society for Vascular Surgery (ESVS) 2025 clinical practice guidelines on the management of diseases of the mesenteric and renal arteries and veins [^113u6WRa]. European Journal of Vascular and Endovascular Surgery (2025). High credibility.

Regarding medical management for renal artery stenosis, more specifically with respect to antihypertensive therapy, ESVS 2025 guidelines recommend to initiate renin-angiotensin system inhibitors, such as ACEis or ARBs, as first-line therapy in patients with unilateral renal artery stenosis and hypertension. Initiate CCBs and thiazide diuretics as first-line additional therapies.

---

### Treatment of resistant and refractory hypertension [^115orAv7]. Circulation Research (2019). Medium credibility.

Resistant hypertension (RHTN) is defined as uncontrolled blood pressure despite the use of ≥ 3 antihypertensive agents of different classes, including a diuretic, usually thiazide-like, a long-acting calcium channel blocker, and a blocker of the renin- angiotensin system, either an ACE (angiotensin-converting enzyme) inhibitor or an ARB (angiotensin receptor blocker), at maximal or maximally tolerated doses. Antihypertensive medication nonadherence and the white coat effect, defined as elevated blood pressure when measured in clinic but controlled when measured outside of clinic, must be excluded to make the diagnosis. RHTN is a high-risk phenotype, leading to increased all-cause mortality and cardiovascular disease outcomes. Healthy lifestyle habits are associated with reduced cardiovascular risk in patients with RHTN. Aldosterone excess is common in patients with RHTN, and addition of spironolactone or amiloride to the standard 3-drug antihypertensive regimen is effective at getting the blood pressure to goal in most of these patients. Refractory hypertension is defined as uncontrolled blood pressure despite use of ≥ 5 antihypertensive agents of different classes, including a long-acting thiazide-like diuretic and an MR (mineralocorticoid receptor) antagonist, at maximal or maximally tolerated doses. Fluid retention, mediated largely by aldosterone excess, is the predominant mechanism underlying RHTN, while patients with refractory hypertension typically exhibit increased sympathetic nervous system activity.

---

### Proteinuria reduction by and safety of finerenone in Chinese patients with CKD without diabetes: a real-world retrospective study [^111rnDn8]. BMC Urology (2025). Medium credibility.

Discussion

This retrospective study evaluated the longitudinal effects of finerenone in 43 Chinese nondiabetic patients with chronic kidney disease (CKD) and focused on changes in 24-hour urinary protein (24-h UTP) levels, estimated glomerular filtration rate (eGFR), and serum potassium levels. The cohort included diverse renal disorders, which predominantly involved membranous nephropathy (46.5%), followed by other CKD aetiologies. Our findings highlight the significant antiproteinuric effect of finerenone (especially in treatment-resistant patients) and provide insights into diagnosis-specific responses and the influence of medication timing, thereby offering valuable perspectives for personalised CKD management.

A key strength of this study involves its focus on patients with persistent proteinuria despite prior treatments with ARBs and sodium-glucose cotransporter-2 (SGLT2) inhibitors, which are established first-line therapies for proteinuria in patients with CKD. This inclusion criterion underscored the notion that the observed median 24-h UTP reduction of 2.76 g (IQR: 0.20–2.61; P < 0.01) occurred in a population with suboptimal responses to guideline-recommended therapies. The additional antiproteinuric effect of finerenone suggests its potential as an adjunctive therapy for patients with refractory proteinuria, which is consistent with evidence from previous studies demonstrating that mineralocorticoid receptor antagonists (MRAs) reduce residual renal risk after renin-angiotensin-aldosterone system (RAAS) blockade and SGLT2 inhibition.

---

### Primary aldosteronism: an endocrine society clinical practice guideline [^1151sGjd]. The Journal of Clinical Endocrinology and Metabolism (2025). High credibility.

Regarding diagnostic investigations for primary aldosteronism, more specifically with respect to plasma aldosterone-to-renin ratio (technical considerations), ES 2025 guidelines recommend to recognize that in hypertensive patients with CKD, renin decreases proportionately to nephron loss, except in cases of renal ischemia from renal artery stenosis where renin will be elevated. Recognize that aldosterone can also be elevated in CKD, leading to overall increases in false-positive testing.

---

### Guidance for incorporating FDA processes into the ACC / AHA clinical practice guideline methodology: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^1142NVDh]. Journal of the American College of Cardiology (2025). High credibility.

Diabetes — renin–angiotensin–aldosterone system inhibition (RAASi): In adults with diabetes and hypertension, ACEI or ARB are recommended in the presence of CKD as identified by eGFR < 60 mL/min/1.73 m² or albuminuria ≥ 30 mg/g and should be considered when mild albuminuria (< 30 mg/g) is present to delay progression of diabetic kidney disease.

---

### Hypertension Canada's 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children [^114bEqKF]. The Canadian Journal of Cardiology (2020). High credibility.

Regarding follow-up and surveillance for primary aldosteronism, more specifically with respect to follow-up, HC 2020 guidelines recommend to recognize that PA is associated with a relative hyperfiltration injury to the kidney in excess of that seen in essential hypertension, and treatment of PA (with either surgery or medical therapy) may unmask significant underlying renal disease with an increase in creatinine and decrease in eGFR. Obtain close monitoring of renal function after treatment.

---

### First-line combination therapy versus first-line monotherapy for primary hypertension [^115Q3UvG]. The Cochrane Database of Systematic Reviews (2020). Medium credibility.

Background

This is the first update of a review originally published in 2017. Starting with one drug and starting with a combination of two drugs are strategies suggested in clinical guidelines as initial treatment of hypertension. The recommendations are not based on evidence about clinically relevant outcomes. Some antihypertensive combinations have been shown to be harmful. The actual harm-to-benefit balance of each strategy is unknown.

Objectives

To determine if there are differences in clinical outcomes between monotherapy and combination therapy as initial treatment for primary hypertension.

Search Methods

The Cochrane Hypertension Information Specialist searched the following databases for randomised controlled trials up to April 2019: the Cochrane Hypertension Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (from 2005), Embase (from 1974), the World Health Organization International Clinical Trials Registry Platform, and ClinicalTrials.gov. We used no language restrictions. We also searched clinical studies repositories of pharmaceutical companies, reviews of combination drugs on the US Food and Drug Administration and European Medicines Agency websites, and lists of references in reviews and clinical practice guidelines.

Selection Criteria

We included randomised, double-blind trials with at least 12 months' follow-up in adults with primary hypertension (systolic blood pressure/diastolic blood pressure 140/90 mmHg or higher, or 130/80 mmHg or higher if participants had diabetes), which compared combination of two first-line antihypertensive drugs with monotherapy as initial treatment. Trials had to include at least 50 participants per group and report mortality, cardiovascular mortality, cardiovascular events, or serious adverse events.

Data Collection and Analysis

Two review authors independently selected trials for inclusion, evaluated the risk of bias, and performed data entry. The primary outcomes were mortality, serious adverse events, cardiovascular events, and cardiovascular mortality. Secondary outcomes were withdrawals due to drug-related adverse effects, reaching blood pressure control (as defined in each trial), and blood pressure change from baseline. Analyses were based on the intention-to-treat principle. We summarised data on dichotomous outcomes as risk ratios (RR) with 95% confidence intervals (CI).

Main Results

This update included one new study in which a subgroup of participants met our inclusion criteria. As none of the four included studies focused solely on people initiating antihypertensive treatment, we asked investigators for data for this subgroup. One study (PREVER-treatment 2016) used a combination of thiazide-type diuretic/potassium-sparing diuretic; as the former is not indicated in monotherapy, we analysed this study separately. The three original trials in the main comparison (monotherapy: 335 participants; combination therapy: 233 participants) included outpatients, mostly European and white people. Two trials only included people with type 2 diabetes; the remaining trial excluded people treated with diabetes, hypocholesterolaemia, or cardiovascular drugs. The follow-up was 12 months in two trials and 36 months in one trial. It is very uncertain whether combination therapy versus monotherapy reduces total mortality (RR 1.35, 95% CI 0.08 to 21.72), cardiovascular mortality (zero events reported), cardiovascular events (RR 0.98, 95% CI 0.22 to 4.41), serious adverse events (RR 0.77, 95% CI 0.31 to 1.92), or withdrawals due to adverse effects (RR 0.85, 95% CI 0.53 to 1.35); all outcomes had 568 participants, and the evidence was rated as of very low certainty due to serious imprecision and for using a subgroup that was not defined in advance. The confidence intervals were extremely wide for all important outcomes and included both appreciable harm and benefit. The PREVER-treatment 2016 trial, which used a combination therapy with potassium-sparing diuretic (monotherapy: 84 participants; combination therapy: 116 participants), included outpatients. This trial was conducted in Brazil and had a follow-up of 18 months. The number of events was very low and confidence intervals very wide, with zero events reported for cardiovascular mortality and withdrawals due to adverse events. It is very uncertain if there are differences in clinical outcomes between monotherapy and combination therapy in this trial.

Authors' Conclusions

The numbers of included participants, and hence the number of events, were too small to draw any conclusion about the relative efficacy of monotherapy versus combination therapy as initial treatment for primary hypertension. There is a need for large clinical trials that address the review question and report clinically relevant endpoints.

---

### Angiotensin II (Giapreza) [^116wud98]. FDA (2024). Medium credibility.

4. CONTRAINDICATIONS

None.

None (4.1)

---

### 2023 AHA / ACC / ACCP / ASPC / NLA / PCNA guideline for the management of patients with chronic Coronary disease: a report of the American Heart Association / American college of cardiology joint committee on clinical practice guidelines [^1156g94y]. Journal of the American College of Cardiology (2023). High credibility.

Regarding specific circumstances for hypertension, more specifically with respect to patients with coronary artery disease, ACC/ACCP/AHA/ASPC/NLA/PCNA 2023 guidelines recommend to initiate guideline-directed medical therapy with ACEis, ARBs, or β-blockers as first-line therapy for compelling indications (such as recent myocardial infarction or angina) in adult patients with chronic coronary disease and HTN (SBP ≥ 130 mmHg and/or DBP ≥ 80 mmHg), in addition to nonpharmacological strategies. Initiate additional antihypertensive medications (such as dihydropyridine CCBs, long-acting thiazide diuretics, and/or mineralocorticoid receptor antagonists) as needed to optimize BP control.

---

### Blood pressure lowering efficacy of renin inhibitors for primary hypertension [^114o2Z1R]. The Cochrane Database of Systematic Reviews (2008). Low credibility.

Background

Hypertension is a chronic condition associated with an increased risk of mortality and morbidity. The renin-angiotensin-aldosterone system is an important target site for five antihypertensive drug classes: beta blockers, renin inhibitors, ACE inhibitors, angiotensin receptor blockers (ARBs) and aldosterone inhibitors. Renin is the enzyme responsible for converting angiotensinogen to angiotensin I, which is then converted to angiotensin II. Renin inhibitors prevent the formation of both angiotensin I and angiotensin II. Renin inhibitors do not affect kinin metabolism and may produce fewer adverse effects than ACE inhibitors such as dry cough or angioedema.

Objectives

To quantify the dose-related blood pressure lowering efficacy of renin inhibitors versus placebo in the treatment of primary hypertension.

Search Strategy

We searched the following databases for randomised, double blind, placebo-controlled trials of renin inhibitors: Medline (1966-March 2008), EMBASE (1988-March 2008), Cochrane CENTRAL, and bibliographic citations from retrieved references. No language restrictions were applied.

Selection Criteria

Study design had to meet the following criteria: double-blinded, placebo-controlled; random allocation to a specific dose of renin inhibitor group and parallel placebo group; duration of follow-up of at least three weeks.

Data Collection and Analysis

Two reviewers independently extracted data and assessed trial quality using risk of bias tables. Disagreements were resolved by discussion or a third reviewer. Data synthesis and analyses were done using the Cochrane Review Manager software, RevMan 5. Data for continuous variables were combined using a weighted mean difference method. Dichotomous variables were analysed using relative risk.

Main Results

Six trials (N = 3694) met the inclusion criteria for this review. Aliskiren was the only renin inhibitor studied in these studies. The meta-analysis shows that aliskiren has a dose-related both systolic/diastolic blood pressure lowering effect as compared to placebo: aliskiren 75 mg -2.9/-2.3 mmHg, aliskiren 150 mg -5.5/-3.0 mmHg, aliskiren 300 mg -8.7/-5.0, aliskiren 600 mg -11.4/-6.6 mmHg. Aliskiren 300 mg significantly lowered both SBP and DBP as compared to aliskiren 150 mg (SBP:-2.97 (95% CI -3.99, -1.95) and DBP: -1.66 (95% CI -2.32, -1.0). Aliskiren has no effect on blood pressure variability. No data was available to assess the effect of aliskiren on heart rate and pulse pressure. This review found weak evidence that with short- term use, aliskiren does not increase withdrawals due to adverse effects as compared to placebo.

Authors' Conclusions

Aliskiren has a dose-related blood pressure lowering effect better than placebo. This effect is similar to that determined for ACE inhibitors and ARBs.

---

### Cardiovascular disease and risk management: standards of care in diabetes – 2025 [^11236uZW]. Diabetes Care (2025). High credibility.

Hypertension in diabetes with albuminuria (Recommendation 10.11): An ACE inhibitor or ARB, at the maximum tolerated dose indicated for blood pressure treatment, is the recommended first-line treatment for hypertension in people with diabetes and urinary albumin-to-creatinine ratio ≥ 300 mg/g creatinine or 30–299 mg/g creatinine, and if one class is not tolerated, the other should be substituted.

---

### Management of primary aldosteronism and mineralocorticoid receptor-associated hypertension [^1157ktPN]. Hypertension Research (2020). Medium credibility.

Resistant hypertension is associated with a poor prognosis due to organ damage caused by prolonged suboptimal blood pressure control. The concomitant use of mineralocorticoid receptor (MR) antagonists with other antihypertensives has been shown to improve blood pressure control in some patients with resistant hypertension, and such patients are considered to have MR-associated hypertension. MR-associated hypertension is classified into two subtypes: one with a high plasma aldosterone level, which includes primary aldosteronism (PA), and the other with a normal aldosterone level. In patients with unilateral PA, adrenalectomy may be the first-choice procedure, while in patients with bilateral PA, MR antagonists are selected. In addition, in patients with other types of MR-associated hypertension with high aldosterone levels, MR antagonists may be selected as a first-line therapy. In patients with normal aldosterone levels, ARBs or ACE inhibitors are used as a first-line therapy, and MR antagonists may be used as an add-on agent. Since MR antagonist therapy may have efficacy as a first-line or add-on agent in these patients, it is important to recognize this type of hypertension. Further studies are needed to elucidate the pathogenesis and management of MR-associated hypertension in more detail to improve the clinical outcomes of patients with MR-associated hypertension.

---

### First-line renin-angiotensin system inhibitors vs. other first-line antihypertensive drug classes in hypertensive patients with type 2 diabetes mellitus [^111X6rU3]. Journal of Human Hypertension (2018). Low credibility.

First-line renin-angiotensin system (RAS) inhibitors are recommended for diabetic patients because of their potential nephron-protective properties. For hypertensive patients with type 2 diabetes mellitus, little is known about first-line RAS inhibitors vs. other first-line antihypertensive agents in terms of cardiovascular outcomes. We performed a meta-analysis of randomized controlled trials (RCTs) to assess the comparative efficacy of first-line RAS inhibitors vs. other first-line antihypertensive drug classes in hypertensive patients with type 2 diabetes mellitus. We identified RCTs by searching the Cochrane Central Register of Controlled Trials, MEDLINE and EMBASE up to December 15, 2015. Eighteen RCTs involving 18,862 participants were included. First-line RAS inhibitors were not different from first-line diuretics for all the primary outcomes. First-line RAS inhibitors reduced major cardiovascular events (2 RCTs, relative risk [RR] 0.78, 95% confidence interval [CI] 0.66, 0.91) and heart failure (4 RCTs, RR 0.72, 95% CI 0.61, 0.83) compared to first-line calcium channel blockers. Compared to β-blockers, RAS inhibitors reduced the risk of all-cause mortality (1 RCT, RR 0.63, 95% CI 0.47, 0.84), major cardiovascular events (1 RCT, RR 0.76, 95% CI 0.62, 0.93) and heart failure (1 RCT, RR 0.60, 95% CI 0.40, 0.92). Our meta-analysis indicates that, in patients with type 2 diabetes mellitus and hypertension, first-line RAS inhibitors reduced adverse cardiovascular events to the same degree as first-line diuretics but to a greater degree than first-line calcium channel blockers and first-line beta blockers.

---

### Adverse effects of aldosterone: beyond blood pressure [^114jkR9i]. Journal of the American Heart Association (2024). Medium credibility.

Aldosterone, and Elevated BP

The primary and evolutionary role of aldosterone is to facilitate potassium excretion and sodium retention, allowing for expansion of circulating volume and maintenance of BP in the face of renally sensed hypoperfusion or volume depletion. It is well established that overt primary aldosteronism (PA), a condition of chronic and maladaptive aldosterone production that is relatively independent of its usual regulatory pathways, is a cause of often severe or resistant hypertension. However, epidemiologic evidence across multiple populations has demonstrated that even in the general population, greater aldosterone concentrations are associated with higher BP and the future risk of incident hypertension. In the Framingham Heart Study, each quartile increase in aldosterone was associated with a 16% to 17% increase in the risk of rising BP and incident hypertension. Similarly, a greater aldosterone‐to‐renin ratio was associated with a higher incidence of progression of BP category and incident hypertension in Framingham, and greater aldosterone levels in the context of renin suppression were associated with greater incidence of new‐onset hypertension, as well as greater urinary potassium excretion, among normotensive participants in the Multi‐Ethnic Study of Atherosclerosis, implicating both greater aldosterone production and MR activity in the development of hypertension. In the Jackson Heart Study, higher aldosterone concentrations and lower renin activity were associated with higher ambulatory BP measurements and adverse BP profiles, again recapitulating the pathophysiology of PA and its characteristic chronic excess activity of the aldosterone–MR axis. Concordantly, in resistant hypertension, treatment with MR antagonists has been demonstrated to reduce BP and mitigate treatment resistance, especially when aldosterone concentrations are elevated. Thus, there is highly consistent evidence across community populations supporting the role of aldosterone and MR activation in the development and propagation of elevated pressure. Though actions of aldosterone as an agonist of MR in the renal collecting duct epithelium and the resulting sodium and volume retention are known to cause elevated BP, and hypertension is a well‐established risk factor for adverse cardiovascular, cerebrovascular, and renal outcomes, the widespread tissue distribution of the MR and evidence from preclinical models and human disease states have made it clear that aldosterone–MR activity has pathologic consequences over and above those caused by hypertension alone.

---

### Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study [^112Sm5mt]. Hypertension Research (2019). Medium credibility.

Introduction

Aldosterone, the final product of the renin–angiotensin system (RAS), is involved in the regulation of blood electrolytes and body fluid volume by acting on the mineralocorticoid receptor (MR), a nuclear receptor in renal tubular and intestinal epithelial cells, to promote Na + reabsorption and K + excretion. Aldosterone also reduces the production of nitric oxide, a vascular relaxing factor, via MRs in vascular endothelial cells and acts directly on vascular smooth muscle to constrict blood vessels. MR blockers, including spironolactone and eplerenone, have been developed and are commercially available as antihypertensive agents. Moreover, MR stimulation is associated not only with hypertension but also with organ damage. The sustained activation of renal MRs is implicated in metabolic diseases, such as diabetes, via RAS-dependent and independent mechanisms, and can ultimately cause kidney damage independent of blood pressure (BP).

Hypertension frequently presents with type 2 diabetes as a comorbidity, and hypertensive patients with diabetes tend to be resistant to treatment. Furthermore, patients with resistant hypertension have a high risk of cardiovascular events, so strict BP control is required. For the treatment of hypertensive patients with diabetes and albuminuria, an angiotensin II receptor blocker (ARB) or an angiotensin converting enzyme (ACE) inhibitor is recommended as a first-line treatment. However, because a considerable proportion of hypertensive patients with diabetes cannot achieve the target BP or adequate end-organ protection with ARB or ACE inhibitors alone, add-on antihypertensive medications are required. Moreover, for those with albuminuria, antihypertensive medications with a renoprotective effect are required.

For patients with diabetic nephropathy, a significant reduction in BP has been achieved with the administration of an MR blocker as an add-on therapy to an ARB or ACE inhibitor. However, one currently available MR blocker, eplerenone, is rarely used in hypertensive patients with renal dysfunction or type 2 diabetes. This is because, in Japan, eplerenone is contraindicated in hypertensive patients with diabetes and concomitant albuminuria, microalbuminuria, or proteinuria, or in patients with a creatinine clearance of < 50 mL/min, due to the considerable risk of increased serum K + levels seen in clinical studies.

---

### Management of hypertension in patients with chronic kidney disease and diabetes mellitus [^114qpKHb]. The American Journal of Medicine (2008). Low credibility.

Treatment of patients at high risk for developing cardiovascular disease aims at controlling blood pressure, optimizing blood glucose levels, and providing renoprotection. Chronic kidney disease (CKD) and diabetes mellitus are prevalent causes of cardiovascular disease owing to associations with major cardiovascular risk factors, such as hypertension, and they are substantial health burdens. Even mild-to-moderate CKD and prehypertension increase cardiovascular risk. First-line agents for reducing cardiovascular risk are inhibitors of the renin-angiotensin system: angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs). In clinical trials, treatment of high-risk patients with ACE inhibitors and ARBs delays or prevents the onset of diabetes and prevents progression of renal disease and cardiovascular events, including cardiovascular mortality. Current evidence indicates that the clinical efficacy of these end points includes effects that may be beyond blood pressure reduction.

---

### Blood pressure changes after catheter-based renal denervation are related to reductions in total peripheral resistance [^113NG49D]. Journal of Hypertension (2015). Low credibility.

Background

Renal denervation (RDN) can reduce sympathetic activity and blood pressure (BP) in patients with uncontrolled hypertension. The exact mechanisms by which RDN results in BP reductions are yet not fully established.

Methods and Results

This study investigated the effects of RDN on office BP, 24-h ambulatory BP, noninvasive 10-min beat-to-beat digital pulse wave analysis, total peripheral resistance (TPR), cardiac output, and plasma renin and aldosterone serum concentrations in 30 patients with resistant hypertension. Adherence to antihypertensive drugs was assessed by liquid chromatography high-resolution tandem mass spectrometry analysis in plasma and urine at baseline and at 6 month. RDN significantly reduced office BP, beat-to-beat BP, and 24-h ambulatory BP by 19/6 (P = 0.021/P = 0.012), 12/7 (P = 0.005/P = 0.005), and 10/5 mmHg (P = 0.001/P = 0.049) at 6 months, respectively. TPR decreased from 1696 to 1377 dyn×s/cm (-19%; P = 0.027). This reduction was not associated with significant changes in cardiac output. The changes in office, ambulatory, and beat-to-beat BP correlated with the reductions of TPR. Adherence to antihypertensive treatment remained unchanged during the study period (84.7% at baseline, 83.6% at 6 months, P = 0.782).

Conclusion

RDN reduced office BP, beat-to-beat BP, and 24-h ambulatory BP in patients with resistant hypertension after 6 months. The BP changes were associated with reductions in peripheral resistance, whereas cardiac output, plasma renin, and aldosterone levels remained unchanged. The observed effects were not explained by an increased intake of antihypertensive medications.

---

### Primary aldosteronism: an endocrine society clinical practice guideline [^1155uohD]. The Journal of Clinical Endocrinology and Metabolism (2025). High credibility.

Primary aldosteronism (PA) screening — aldosterone, renin, and aldosterone–renin ratio (ARR) thresholds and repeat-testing guidance are as follows: plasma renin activity (PRA) is ≤ 1 ng/mL/h or direct renin concentration (DRC) is ≤ 2.8 mU/L and serum/plasma aldosterone concentration is ≥ 10 ng/dL (≥ 277 pmol/L) by immunoassay or ≥ 7.5 ng/dL (≥ 208 pmol/L) by liquid chromatography–tandem mass spectrometry (LC-MS/MS). Elevated ARR is indicative of PA if the aldosterone [ng/dL] to PRA [ng/mL/h] ratio is > 20 or aldosterone [pmol/L] to DRC [mU/L] ratio is > 70 when aldosterone is measured by immunoassay; the ARR indicative of PA is about 25% lower when aldosterone is measured by LC-MS/MS. If the initial screen is negative and factors could have led to a false-negative result, the test should be repeated on a different day after correcting hypokalemia and withdrawing interfering medications for 4 weeks for mineralocorticoid receptor antagonists, epithelial sodium-channel inhibitors, and other diuretics, and 2 weeks for angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. If the initial screen is negative and the pretest probability of PA is moderate to high, or renin is suppressed with aldosterone of 5 to 10 ng/dL (138 to 277 pmol/L) by immunoassay, the test should be repeated on a different day. If the initial screen is positive but the patient is receiving β-adrenergic blockers or centrally acting α2-agonists that can lower renin and cause false-positive results, the test should be repeated after withdrawing those medications for 2 weeks; consider potential false positives induced by β-adrenergic blockers when aldosterone is 10 to 15 ng/dL (277–416 pmol/L) by immunoassay or 7.5 to 10 ng/dL (208–277 pmol/L) by LC-MS/MS, and if aldosterone is above these concentrations, PA is likely despite β-adrenergic blockers. In chronic kidney disease, renin decreases proportionally to nephron loss while aldosterone can be elevated, leading to overall increases in false-positive testing. If all initial screening is negative, consider rescreening in the future if a patient develops unexplained worsening of hypertension or resistant hypertension, new spontaneous or diuretic-induced hypokalemia, or atrial fibrillation in the absence of structural heart disease or hyperthyroidism.

---

### 2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the international society of hypertension (ISH) and the European renal association (ERA) [^114Vx2JC]. Journal of Hypertension (2023). High credibility.

Regarding medical management for hypertension, more specifically with respect to choice of antihypertensives, initial therapy, ESH 2023 guidelines recommend to use drugs from the five major drug classes, including ACEis, ARBs, β-blockers, CCBs, and thiazide/thiazide-like diuretics and their combinations, as the basis for antihypertensive treatment strategies to reduce BP and cardiovascular events.

---

### Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin-receptor blockers [^116s9Qfm]. Current Opinion in Nephrology and Hypertension (2005). Low credibility.

Purpose Of Review

To review the antihypertensive, cardiovascular and pleiotropic effects of angiotensin-receptor blockers (ARBs).

Recent Findings

ARBs are the most recently approved class of antihypertensive agents. They selectively block the angiotensin II type 1 receptor, thus inhibiting most of the deleterious effects of angiotensin II. In addition to blood-pressure control, other benefits may be gained using ARBs. This is because the renin-angiotensin system plays a crucial role in circulatory homoeostasis, and in patients with atherosclerosis, diabetes or hypertension, angiotensin II contributes to the pathophysiology of disease. Evidence-based medicine includes well-controlled studies with mortality and morbidity endpoints in patients with a variety of conditions including hypertension, type 2 diabetes, stroke, renal disease, heart failure, left-ventricular hypertrophy and coronary heart diseases. In addition to these hard endpoints, it has been shown that treatment with ARBs prevents the development of type 2 diabetes, ameliorates coronary and peripheral vascular endothelial dysfunction and decreases plasma levels of several markers of vascular inflammation.

Summary

ARBs are first-line agents for the treatment of hypertension and cardiovascular diseases. Blocking the renin-angiotensin system with these agents has special advantages due to specific vascular and antiatherosclerotic effects, which contribute to a better cardiovascular and renal protection in patients at risk from or with cardiovascular disease.

---

### 2025 AHA / ACC / AANP / AAPA / ABC / ACCP / ACPM / AGS / AMA / ASPC / NMA / PCNA / SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^116GyidC]. Hypertension (2025). High credibility.

Regarding medical management for hypertension, more specifically with respect to choice of antihypertensives, initial therapy, AANP/AAPA/ABC/ACC/ACCP/ACPM/AGS/AHA/AMA/ASPC/NMA/PCNA/SGIM 2025 guidelines recommend to initiate thiazide-type diuretics, long-acting dihydropyridine CCBs, and ACEis or ARBs as first-line therapy to prevent CVD in patients initiating antihypertensive drug therapy.

---

### American association of clinical endocrinology consensus statement: comprehensive type 2 diabetes management algorithm-2023 update [^117ACkuE]. Endocrine Practice (2023). High credibility.

AACE ASCVD risk reduction algorithm — hypertension specifies a blood pressure goal of < 130 systolic/ < 80 diastolic mmHg, highlights lifestyle intervention, and states to titrate medication dose or add other therapy every 2–3 months to reach goal. Listed medication options include thiazide and calcium channel blocker; β blocker β₁ selective and mineralocorticoid RA; and additional antihypertensive agents central α-agonist, peripheral α₁-blocker, and hydralazine.

---

### Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study [^113UWHXU]. Journal of Human Hypertension (2019). Medium credibility.

Introduction

Hypertension is a multifactorial disease involving complex interactions between various metabolic, neurohormonal, and inflammatory factors, and is a leading risk factor for cardiovascular morbidity and mortality. Uncontrolled hypertension is associated with vasculopathy, heart disease, cerebrovascular diseases, and nephropathy, all of which are classic manifestations of hypertensive end-organ damage.

In addition to non-pharmacological treatments, management of hypertension often requires pharmacotherapy with an antihypertensive agent, which is a proven approach for reducing cardiovascular morbidity and mortality. Although monotherapy may be effective in some patients, failure to achieve the desired antihypertensive effect requires the concurrent use of multiple antihypertensive drugs as part of a multifactorial strategy. In fact, many patients require three or more antihypertensive drugs to achieve a blood pressure (BP) level of < 140/90 mmHg. Triple drug therapy combinations usually include a renin–angiotensin system inhibitor (angiotensin converting enzyme [ACE] inhibitors or angiotensin II-receptor blockers), a calcium channel blocker, and a diuretic.

The Japanese Guidelines for the Management of Hypertension (2014) recommend adding an aldosterone antagonist to the treatment regimen of patients with poorly controlled BP or resistant hypertension. Aldosterone is a steroid hormone that regulates electrolyte homeostasis and BP via binding to the mineralocorticoid receptors (MR) in the distal tubule and collecting duct of the kidney. Primary aldosteronism (PA) is caused by the excess production of aldosterone and is the most common cause of secondary hypertension as well as a common cause of antihypertensive treatment resistance. Furthermore, aldosterone-induced MR activation impairs insulin sensitivity and is associated with obesity and diabetes. Therefore, treatment-resistant hypertension in the presence of conditions such as obesity, diabetes, and chronic kidney disease (CKD) can occur despite normal plasma aldosterone concentrations (PAC). The role of pathological overstimulation of MR in the absence of high aldosterone levels has been indicated in cases of MR-associated hypertension.

---

### KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease [^114Eks7z]. American Journal of Kidney Diseases (2007). Medium credibility.

Guideline 3: Management of hypertension in diabetes and CKD — Most people with diabetes and CKD have hypertension, and treatment of hypertension slows the progression of CKD. Hypertensive people with diabetes and CKD stages 1–4 should be treated with an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB), usually in combination with a diuretic.

---

### Hypertension Canada's 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children [^115hsw1Z]. The Canadian Journal of Cardiology (2020). High credibility.

Regarding medical management for hypertension, more specifically with respect to choice of antihypertensives, initial therapy, HC 2020 guidelines recommend to do not use α-blockers as first-line therapy in patients with uncomplicated HTN. Do not use β-blockers as first-line therapy in ≥ 60 years old patients with uncomplicated HTN. Do not use ACEis as first-line therapy in black patients with uncomplicated HTN.

---

### Fosinopirl sodium (fosinopril sodium) [^112zsddM]. FDA (2023). Medium credibility.

General

Impaired Renal Function

As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals. In patients with severe congestive heart failure whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with angiotensin-converting enzyme inhibitors, including fosinopril sodium tablets, may be associated with oliguria and/or progressive azotemia and (rarely) with acute renal failure and/or death.

In hypertensive patients with renal artery stenosis in a solitary kidney or bilateral renal artery stenosis, increases in blood urea nitrogen and serum creatinine may occur. Experience with another angiotensin-converting enzyme inhibitor suggests that these increases are usually reversible upon discontinuation of ACE inhibitor and/or diuretic therapy. In such patients, renal function should be monitored during the first few weeks of therapy. Some hypertensive patients with no apparent preexisting renal vascular disease have developed increases in blood urea nitrogen and serum creatinine, usually minor and transient, especially when fosinopril sodium has been given concomitantly with a diuretic. This is more likely to occur in patients with preexisting renal impairment. Dosage reduction of fosinopril sodium and/or discontinuation of the diuretic may be required.

Evaluation of patients with hypertension or heart failure should always include assessment of renal function (see DOSAGE AND ADMINISTRATION).

Impaired renal function decreases total clearance of fosinoprilat and approximately doubles AUC. In general, no adjustment of dosing is needed. However, patients with heart failure and severely reduced renal function may be more sensitive to the hemodynamic effects (e.g., hypotension) of ACE inhibition (see CLINICAL PHARMACOLOGY).

Hyperkalemia

In clinical trials, hyperkalemia (serum potassium greater than 10% above the upper limit of normal) has occurred in approximately 2.6% of hypertensive patients receiving fosinopril sodium. In most cases, these were isolated values which resolved despite continued therapy. In clinical trials, 0.1% of patients (2 patients) were discontinued from therapy due to an elevated serum potassium. Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and other drugs that raise serum potassium levels. Monitor serum potassium in such patients (see PRECAUTIONS, Drug Interactions).

---

### Management of blood glucose in type 2 diabetes mellitus… [^1147ZxpV]. AAFP (2009). Low credibility.

Amylin Analogues Pramlintide is an amylin analogue indicated for use in patients with type 1 diabetes; it is rarely used to manage type 2 diabetes. 11 When pramlintide is initiated, the insulin dosage should be reduced by 50 percent to avoid potentially severe hypoglycemia. There is insufficient evidence to make conclusions about the effects of pramlintide on cardiovascular disease.
17. 14 Metformin is a first-line consideration. Gastrointestinal symptoms associated with its use can be minimized by beginning with a low dose and titrating slowly. Additional agents include sulfonylureas, nonsulfonylurea secretagogues, thiazolidinediones, and alpha-glucosidase inhibitors. Any of these agents can be combined with another. Once fasting blood glucose approaches near-normal levels, postprandial glucose is addressed by increasing the dose of the current medications or by adding additional agents.

Once maximal benefit is achieved from first-line medications, other agents, such as exenatide and sitagliptin, can be considered. INITIATING INSULIN THERAPY Less than 40 percent of patients with diabetes successfully achieve an A1C level of less than 7 percent. Newly diagnosed patients also can benefit from acute insulin use. Prolonged hyperglycemia can cause glucose toxicity, a potentially reversible impairment in glucose-stimulated insulin secretion. This can be corrected with aggressive insulin therapy, then oral medications can be added as insulin is tapered or discontinued. Expert opinion suggests that insulin therapy should be initiated if the fasting blood glucose level is consistently greater than 250 mg per dL, or if random testing shows levels greater than 300 mg per dL 24.

7, 27 The increased prevalence of comorbid conditions in older adults requires careful consideration of medications. Serum creatinine levels are not always a reliable predictor of renal insufficiency in the elderly, so metformin should be used with caution. The high prevalence of heart failure in this population limits the use of thiazolidinediones. Older patients are likely to benefit more from aggressive management of known cardiovascular disease risk factors such as hypertension than by tight glycemic control, which can increase symptomatic hypoglycemia. 7.